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ABSTRACT
This research features the isolation, structural elucidation, and synthesis of natural products
from rare and endangered plant species and marine sponges.
Part I elaborates the identification of bioactive phytochemicals from several rare or
endangered plant species including Lindera melissifolia, Rhododendron brachycarpum, and
Diplostephium rhododendroides. Worldwide at least 13% of known flora are endangered or
threatened and the United States Department of Agriculture (USDA) reported that there are over
780 endangered or threatened plant species in the US and its territories. The essential oil and
solvent extracts from L. melissifolia (pondberry) drupes were gathered, purified, and analyzed by
various spectrometric techniques. The essential oil exhibited a significant dose dependent repellent
activity against ticks reported to be vectors of significant pathogenic human diseases such Lyme
disease. A Korean endangered plant R. brachycarpum was also rigorously investigated for
bioactive molecules. R. brachycarpum is a broad-leaved shrub native to northern parts of Korea
and Japan. The high mobility group box 1 protein (HMGB1) could be a specific target for the
discovery of effective agents to alleviate severe sepsis. The first bicyclic megastigmane glucoside
rhododendroside A was isolated from the leaves of R. brachycarpum. Gauge-invariant atomic
orbital (GIAO) NMR chemical shift calculations were implemented for elucidation of
stereochemical details of rhododendroside A with accuracy improved by application of DP4
analysis. One of the rare South American plant species D. rhododendroides Hieron. afforded
diplostephiosides A and B. These secondary metabolites exerted inhibitory activity of protein
tyrosine phosphatase 1B (PTP1B) that has captured widespread attention in development of agents
ii

for the treatment of metabolic disorders. Comprehensive induced-fit docking simulations were
implemented with diplostephiosides A and B and they demonstrated excellent docking scores with
the allosteric binding sites.
Part II delineates not only the characterization of the stereostructure of BRCA1-IRIS (IRIS)
inhibitory peptide exhibiting potent in vivo cytotoxic activity on triple-negative breast cancer
(TNBC) but also the partial synthesis of a sponge-derived cytotoxic drug prototype for treatment
of pancreatic cancer. Breast cancer is the second most diagnosed cancer in American women.
Based on a recent study corroborating that the oncogenicity of IRIS resides with the intron 11
peptide domain, an IRIS-inhibitory peptide (IRIS-IP), composed of the oncogenic intron sequence
attached to a nuclear penetrating signal, was designed and its 3D structure was elucidated utilizing
high-field NMR spectroscopic and computational tools.

Pancreatic cancer has also been

recognized as a major cause of death in the West. In 2015, an estimated 48,960 people in the US
will be diagnosed with pancreatic cancer and about 20,710 will die from the serious disease.
Discorhabdin X, isolated from Latrunculia species collected in the deep waters off the Aleutian
Islands, possesses intriguing ring systems and exhibited selective cytotoxic activity on pancreatic
cancer. A partial structural moiety of this antineoplastic molecule is being synthesized to further
evaluate in vivo cytotoxic activity for the development of a practical drug prototype targeting the
treatment of pancreatic cancer and its related fatalities.
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PART I: INVESTIGATION OF GLOBAL ENDANGERED SPECIES FOR NEW
CHEMISTRY AND DRUG PROTOTYPES

CHAPTER 1
INVESTIGATION OF TICK REPELLENT ACTIVITY OF VOLATILES FROM THE
SOUTHEASTERN US ENDANGERED PLANT LINDERA MELISSIFOLIA

CHAPTER 2
CONFIGURATIONAL ASSIGNMENT OF CONFORMATIONALLY RESTRICTED
MEROTERPENOIDS FROM L. MELISSIFOLIA
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ENDANGERED SPECIES RHODODENDRON BRACHYCARPUM

CHAPTER 4
SCRUTINY OF THE SOUTH AMERICAN ENDANGERED SPECIES DIPLOSTEPHIUM
RHODODENDROIDES FOR ANTIDIABETIC DRUG LEADS CAPABLE OF INHIBITING
PROTEIN TYROSINE PHOSPHATASE 1B
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CHAPTER 1: INVESTIGATION OF TICK REPELLENT ACTIVITY OF VOLATILES
FROM THE SOUTHEASTERN US ENDANGERED PLANT LINDERA MELISSIFOLIA
(The contents of this Chapter were reprinted or modified from the original article published in
Phytochemistry with permission from the publisher via Rightslink® service, Copyright 2012
Elsevier B.V., Confirmation No. 11305540)
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INTRODUCTION
A recent report on the decline of global biodiversity suggests that the rate has not decreased
and several factors have worsened the decline.1 The pressure on biodiversity has been recognized
for several years, yet progress toward limiting exacerbating factors worldwide appears sluggish.
Globally at least 13% of known flora are endangered or threatened2 and the United States
Department of Agriculture (USDA)3 claimed that there are currently at least 780 endangered or
threatened species of plants in the United States (US) and its territories. Although environmental
factors such as habitat destruction, fragmentation, and climate change4 are the most widespread
causes of plant species endangerment worldwide,4 biological threats such as competition with nonnative species and invasion of fungi,5 viruses,6 and exotic arthropods7 are also significant factors
driving those species to extinction.
The Lauraceae are comprised of about 55 genera and over 2000 species are found in the
family.8 The members are generally known for their high content of essential oils used in the
perfume and spice industries.8 Several studies on essential oils found in this family reveal
associated chemistry and a variety of bioactivities.9-13

Lindera melissifolia (Walt.) Blume

(Lauraceae), commonly known as pondberry, is a member of the Lauraceae family but has not
been investigated for its potential bioactive constituents. It is an aromatic, rhizomatous, dioecious
shrub that grows in seasonally flooded wetlands and on the edges of sinks and ponds in the
Southeastern US.14,15 The US Fish and Wildlife Service (USFWS) listed pondberry as an
endangered species in 198616 because of habitat loss.15
During the past approximately 30 years, Lyme disease has become a major human health
problem in the US with many cases reported annually.17,18 In New England, the Mid-Atlantic, and
the Great Lake areas the causative spirochete Borrelia burgdorferi is transmitted by the bite of the
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blacklegged tick Ixodes scapularis whereas the Pacific blacklegged tick Ixodes pacificus is the
vector of the pathogenic spirochete on the West Coast.19,20 The lone star tick Amblyomma
americanum is another tick species of medical and veterinary importance21 and this arthropod has
spread from South Central and Southeastern states northward and somewhat westward into the
Mid-Atlantic US states.22
With proper application, insect repellents reduce disease transmission caused by arthropod
vectors.23 N, N-diethyl-3-methylbenzamide (DEET) is a broad-spectrum synthetic repellent that
has been effective against several species of mosquitoes, chiggers, ticks, and biting flies.24-28
However, repeated use of synthetic repellents disrupts natural biological systems and promotes
resistance.23,29 Additionally, DEET has been reported to exert toxic reactions in humans under
certain circumstances and age groups,30,31 which motivates exploration and development of natural
product-based repellents.
Plants are considered to be a source of safe repellents since they may have less harmful
side effects from regular use.32 A number of essential oils from plants exhibit insect repellent
properties.32 Natural repellents are commonly regarded to be effective for short durations but some
botanically based repellents such as p-menthane-3,8-diol from the lemon-scented gum tree
Corymbia citriodora have recently shown sustained potency for protection against mosquitoes.33,34
Consequently, more interest has been focused on plant extracts or essential oils as potential
alternative repellent agents.35
As part of a conscious effort to conserve plant resources that still exist in the US but are
threatened with extinction, L. melissifolia is investigated herein for the chemical constituents and
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potential biomedical herein. The crude essential oil of fresh pondberry drupes was collected and
the oil and a hexanes extract were evaluated for tick-repellent activity.

Figure 1. 1H NMR spectrum of pondberry essential oil and the identified major components
(CDCl3, 400 MHz) (i) (E)-β-ocimene, (ii) (±)-sabinene, (iii) (±)-α-phellandrene, (iv) (±)-limonene,
(v) p-cymene, (vi) myrcene
RESULTS AND DISCUSSION
Crude Essential Oil Analysis/ Preliminary Tick Repellent Assay
Gas chromatography (GC) and GC-MS analyses were used to investigate the components
of the essential oil and hexanes extract from L. melissifolia drupes (Table 1). The major
components of the essential oil were (±)-sabinene (66.2%), (E)-β-ocimene (12.9%), (±)-αphellandrene (4.1%), β-caryophyllene (2.6%), (±)-limonene (2.3%), myrcene (2.1%), and pcymene (0.5%), the structures of which were confirmed by 1D NMR analysis. In the 1H NMR
spectrum (Figure 1), the characteristic and strong resonances for exo-olefinic (4.65–4.84 ppm)
3

and cyclopropyl functional groups (0.66–0.68 ppm) were observed in component (ii), indicating
the presence of (±)-sabinene which was proven to be the most abundant component in the essential
oil by GC and GC-MS analyses (Table 1). The presence of a noticeable resonance for component
(i) at 6.39 ppm displaying typical cis and trans vicinal couplings (dd, J=17.6, 10.7 Hz) implied the
presence of a monosubstituted vinyl group. Comparison of the 13C NMR chemical shift values
and their relative intensities with literature data36 revealed that component (i) is (E)-β-ocimene.
An aromatic signal resonated at 7.13 ppm (d, J=2.3 Hz) for component (v) suggested the presence
of a phenyl group. Further NMR analysis characterized the component as p-cymene. Additionally,
normal phase preparative high-performance liquid chromatography (HPLC) provided a minor

Figure 2. Responses of A. americanum nymphs to pondberry extract (A), DEET (B), and
acetone (concentration of zero) in vertical filter paper bioassays. Estimated EC50 (A and B)
and EC95 (B only) indicated by arrows.
component, trans-sabinene hydrate.36
The vertical filter paper bioassay was employed to assess repellent potential of the
pondberry extract against the blacklegged tick I. scapularis and lone star tick A. americanum.
The essential oil at 0.827 mg extract/cm2 filter paper repelled 74% of the A. americanum nymphs
(7.40 ± 0.51 of 10 ticks per replicate) and was significantly more repellent than the acetone
4

5

α-thujene
3-hexanone
α-fenchene
camphene

β-pinene

sabinene
δ-3-carene
myrcene
α-phellandrene
α-terpinene
limonene
1,8-cineole
β-phellandrene
(Z)-β-ocimene
γ-terpinene
(E)-β-ocimene
p-cymene
2-methylbutyl
methyl butyrate

1035
1058
1072
1076

1118

1132
1159
1174
1176
1188
1203
1213
1218
1246
1255
1266
1280

20.2

66.2
0.2
2.1
4.1
0.2
2.3
1.1
0.5
0.2
0.3
12.9
0.5

1.2

0.1
0.1

0.5

1.0

tr

0.4
1.1
tr
0.3
tr
tr
tr
tr
3.0
0.2

17.7

0.3

0.1
0.4

0.1

1733

1553
1572
1589
1591
1600
1612
1659
1668
1687
1704
1706
1726

1542

1487
1497
1544
1549

1474

A% b B% b RRI a
0.2
1290

neryl acetate

Components
terpinolene
trans-sabinene
hydrate
citronellal
α-copaene
α-gurjunene
β-cubebene
cis-sabinene
hydrate acetate
linalool
pregeijerene B
β-ylangene
bornyl acetate
β-elemene
β-caryophyllene
γ-gurjunene
citronellyl acetate
α-humulene
γ-muurolene
α-terpineol
germacrene D
tr

0.1
0.8

0.3
0.1

2.6

0.2

tr
0.2

tr

0.6

0.2

0.4

0.2
0.4
1.1
0.4
1.5
15.5
0.6
1.7
1.5
0.2
0.4
13.4

0.1

1.1
0.4
0.3
0.2

0.5

2509

2008
2069
2096
2187
2226
2255
2257
2260
2369
2431
2456
2492

1857

1772
1773
1807
1808

1765

A% b B% b RRI a
0.5
0.3
1740

methyl linoleate

caryophyllene oxide
germacrene D-4β-ol
elemol
t-cadinol
methyl palmitate
α-cadinol
β-eudesmol
citronellic acid
(2E,6E)-farnesol
methyl stearate
methyl oleate
ethyl oleate

geraniol

citronellol
δ-cadinene
α-cadinene
nerol

geranyl acetate

Components
α-muurolene

tr

tr

0.5

0.2

1.5

0.4
3.9
6.6
0.2
0.3
0.2
0.2
0.4
tr
0.7
2.3
0.2

0.3

4.3
0.7
0.3
tr

2.2

A% b B% b
tr

b

2931 hexadecanoic acid
2.7
RRI: relative retention indices calculated against n-alkanes; Calculated from GC-flame ionization detector (FID) data; tr: trace (<
0.1%); Some components could exist as racemic mixtures

a

α-pinene

1032

1286

Components
Decane

RRI a
1000

Table 1. GC and GC-MS analyses of pondberry crude essential oil (A) and hexanes extract (B) from L. melissifolia drupes

control (P = 0.001). DEET repellence was 93% (9.33 ± 0.67 of 10 ticks per replicate). The fit
of the data for determining half maximal effective concentration (EC50) and 95% maximal
effective concentration (EC95) values, the slopes and intercepts of the regression equations, and
dispersion parameters for the pondberry essential oil and DEET are shown in Figure 2 and
Table 2.
Table 2. Concentrations of L. melissifolia essential oil and DEET estimated to repel 50 and 95%
of A. americanum nymphs
Sample
Essential
Oil
DEET
a

Concentration a (±SE)
EC50 0.668 (sqrt)
EC95 1.250 (sqrt )
EC50 0.339 (sqrt)
EC95 0.731 (sqrt)

(±0.050)
(±1.250)
(±0.058)
(±1.022)

Intercept (±SE)
-3.3820 (±0.695)
-2.546 (±0.719)

Slope (±SE)
5.062
(±1.051)
7.501
(±1.640)

Dispersion
Parameter
2.050
2.663

Concentrations as mg extract or DEET/cm2 filter paper; sqrt: square root; SE: standard error
There was no EC95 determined for repellency of the pondberry essential oil against ticks

because the necessary proportion of ticks was not repelled. The slope of the regression equation
for DEET was significantly higher (P = 0.001) than that of the tested essential oil. At 0.413 mg/cm2
filter paper, the examined essential oil repelled significantly more I. scapularis adults per replicate
(P< 0.0001) with an average of 9.75 ± 0.25 (97.5%) ticks repelled compared to the acetone controls
with 1.67 ± 0.33 (16.1%) adults repelled. This contrasts with A. americanum which required an
estimated 0.668 ± 0.05 mg extract/cm2 filter paper to repel half the ticks (Table 2).
The most abundant component (±)-sabinene was ineffectual (P = 0.3168) against A.
americanum nymphs at 2000 nmole/cm2 filter paper repelling an average of 1.33 ± 0.88 (13.3%)
ticks per replicate. However, the same concentration of trans-sabinene hydrate repelled an average
of 5.0 ± 1.0 (50%) A. americanum nymphs per replicate (P = 0.0398). Pondberry extract is clearly
repellent to A. americanum and I. scapularis and apparently more so to I. scapularis. Other
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repellents (e.g. DEET, SS220) tested in the vertical filter paper bioassay required higher
concentrations to repel A. americanum nymphs than to repel I. scapularis nymphs.37 A minor
constituent, trans-sabinene hydrate (0.2% of the pondberry essential oil), showed some moderate
repellent activity against A. americanum and may act in conjunction with other minor components.

Figure 3. Stacked GC chromatograms of fractions generated by fractional freezing at -20, -42, 61, and -200 °C (from top to bottom)
Enrichment of Active Components in Pondberry Essential Oil
After the crude pondberry oil was shown to be an effective repellent against ticks, a solventefficient method was devised to enrich the active components.

Fractional freezing, which has

been traditionally utilized for purifying solvents using their different freezing points,38,39 was
employed to separate groups of volatile components from the pondberry drupes in this study
(Figure 3 and Table 3). The stacked GC-MS chromatograms of fractions generated by the
7

fractional freezing technique are shown in Figure 3 and components in each fraction were
identified using the aforementioned method (Table 3). The most abundant monoterpene in the
crude oil was (±)-sabinene (retention time: 10-11 min, Figure 3) and likewise it dominated all but
the -20 °C fraction (Table 3). Fractions collected at -20 °C and -42 °C repelled the A. americanum
ticks to a similar extent as the crude oil (Figure 4), indicating that fractional freezing was effective
in accumulating tick repellent components from the essential oil. Comparative analysis of each
fraction (Figure 5 and Table 3) identified previously reported tick repellents [geraniol (S),
citronellol (AF), geranyl acetate (AD), citronellal (Q), terpinen-4-ol (U), and citronellyl acetate
(AB)]40 and suggested that additional components [myrcene

(F), bornyl acetate (T), β-

caryophyllene (W), α-humulene (X), germacrene D (Y), and β-elemene (AE)] also possess
repellent activity.

Figure 4. Mean numbers of A. americanum ticks repelled by pondberry crude oil, fractions (-20,
-42, -61, and -200 °C), and acetone in vertical filter paper bioassay. Columns with the same number
of asterisks do not differ significantly (P > 0.05) according to analysis of variance.
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Table 3. Components (%) identified in the essential oil fractions generated by fractional freezing
technique. *tr=trace
Components

Code

α-pinene
α-thujene
camphene
β-pinene
sabinene
myrcene
α-phellandrene
α-terpinene
limonene
1,8-cineole
(E)-β-ocimene
γ-terpinene
p-cymene
2-methylbutyl 2-methyl butyrate
alloocimene
terpinolene
citronellal
linalool
geraniol
bornyl acetate
terpinen-4-ol
α-terpinyl acetate
β-caryophyllene
α-humulene
germacrene D

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
AA
AB
AC
AD
AE
AF
AG

pregeijerene B

sabina ketone
citronellyl acetate
α-copanene
geranyl acetate
β-elemene
citronellol
caryophyllene oxide

Fractions by Fractional Freezing
-20 °C
-42 °C -61 °C -200 °C
3.20
7.27
7.13
1.52
5.46
3.47
0.45
0.28
0.32
2.67
2.87
9.23
61.42
62.89
70.93
0.43
1.30
0.53
6.66
4.91
2.70
0.47
0.50
4.56
2.16
3.87
1.10
*tr
8.78
1.39
0.85
2.50
3.53
1.21
1.76
1.64
11.04
7.14
4.71
3.30
2.47
0.76
1.77
0.48
0.42
0.52
0.87
1.18
0.54
0.50
2.39
0.55
1.90
0.22
28.90
0.65
1.87
13.80
1.69
0.90
0.08
2.30
0.33
0.12
0.30
3.10
0.29
0.37
1.22
0.61
0.05
8.34
0.17
4.21

% Calculated from areas of each peaks corresponding to each components on GC chromatogram;
tr : trace (< 0.1%); Some components may exist as racemic mixtures
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Relative Presence in Fractions (%)

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

A B D E F G H I J
-200 °C 7.1 3.5 2.9 71
2.7 2.2
2.5
-61 °C 7.3 5.5 2.7 63
4.9 4.6 1.1 0.9
-42 °C 3.2 1.5 0.3 61 1.3 6.7 0.5 3.9 1.4
-20 °C
0.3 9.2 0.4 0.5 0.5
8.8

K L M P Q T U W X Y AB AE AF
1.8 4.7 1.8
1.2 7.1 0.8 1.2
11 2.5 0.9 0.5 0.2 0.7 1.7 0.1 0.3 0.3 0.1 0.2
3.5 1.6 3.3 0.5 0.5 1.9 29 14 0.9 2.3 3.1 0.6 8.3

Figure 5. Scaled distribution of potential tick repellent components in the fractions generated by
fractional freezing. The components detected in only one fraction were excluded for more relevant
analysis. The entire list of components is shown in Table 3.
CONCLUSION
GC and GC–MS analyses of the essential oil from L. melissifolia drupes identified various
mono- and sesqui-terpenoids (Table 1). The major constituent of the pondberry essential oil and
its hexanes extract was (±)-sabinene. The NMR fingerprinting process coupled with GC and GCMS verified that (E)-β-ocimene, (±)-sabinene, (±)-α-phellandrene, (±)-limonene, p-cymene, and
myrcene were characteristic markers of the essential oil from pondberry (Figure 1). The essential
oil repelled both the lone star and blacklegged ticks, which indicates it could be developed into a
nature-derived broad spectrum repellent. Fractional freezing was verified to be an effective and
solvent-efficient method to accumulate the tick repellent components in the pondberry essential
oil. Although extraction with hexanes may provide a similar product (Table 1) it is not clear from
10

our tests if the hexanes extract would be active as a tick repellent. Based on our analysis of the
fractions generated by fractional freezing, β-caryophyllene (W), α-humulene (X), germacrene D
(Y), and β-elemene (AE) warrant further investigation as tick repellents (Figure 5). Although the
reported compounds may be readily obtained from other plant sources or synthetic routes,
agricultural techniques involving strain selection based on the metabolome of the plant may also
satisfy supply requirements. Additionally, the endangered plant metabolome would provide a
valuable tool for strain selection for disease and insect resistance. Thus utilization of products
obtained from endangered or threatened plant species can potentially support their conservation
and commercial development.
EXPERIMENTAL SECTION
General Experiments
NMR spectra were obtained using a Bruker Avance 400 MHz spectrometer referenced by
residual dichloromethane and chloroform resonances. Precoated silica gel 60 F254 plates from
Merck were used for thin-layer chromatography (TLC). Pentane and dichloromethane (4:1) was
used to develop TLC. A vanillin-sulfuric acid stain and iodine were utilized for visualizing TLC.
The application of HPLC was carried out with a Phenomenex silica column (10 × 250 mm, 5 μm)
for semi-preparative injections with a Waters dual pump model 510 (flow rate 8 mL/min) and a
UV absorbance detector model 486. Each fraction was collected employing a Foxy 200 fraction
collector with one minute increment and identified by TLC. DEET and trans-sabinene hydrate
used for the tick assay were purchased from Sigma-Aldrich. The major compound (±)-sabinene
was isolated from the pondberry essential oil with standard chromatography techniques. In
addition to the purchased trans-sabinene hydrate, the monoterpenoid was purified from the
pondberry crude oil utilizing an HPLC method elaborated above.
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Plant Material
The drupes of L. melissifolia (5 kg) were collected in September 2009 at the Flooding
Research Facility (FRF)41 on USFWS land in Sharkey Co., MS, jointly maintained by the USFWS
and US Forest Service. The species was authenticated by Danny Skojac and Tracy Hawkins (US
Forest Service). The drupe sample was combined from plants of nine female clones previously
collected from the Delta National Forest, Sharkey Co., MS and USFWS property in Bolivar Co.,
MS. These clones were reproduced from tissue culture42 and planted into the FRF for a large-scale
physiology experiment. A voucher specimen (# 01157) has been deposited at the Herbarium of
the US Forest Service Southern Hardwoods Laboratory, Washington Co., MS.
Essential Oil Extraction
Pondberry drupes (5 kg) were coarsely ground in a blender and placed in the chamber of a
Speed Vac® (SC210A, Thermo Scientific, Waltham, MA) evaporator. The essential oil was
collected in the glass chamber of a refrigerated vapor trap (ca. 100 °C) (RVT 4104, Thermo
Scientific, Waltham, MA) under high vacuum. The essential oil contents of the trap were defrosted
and collected using a separation funnel or extracted with dichloromethane. Removal of the residual
solvent was completed by carefully blowing with nitrogen gas. The amount of the collected crude
oil was approximately 30 g (0.6% wet weight) and the oil was stored at -20 °C. The remaining
material was extracted three times by ultrasound in hexanes, which yielded 300 g of the hexanes
extract.
GC, GC-MS, and NMR Analysis of Crude Essential Oil
The GC-MS analysis was carried out with an Agilent 5975 GC-mass selective detector
system. A fused silica capillary column (60 m × 0.25 mm, 0.25 m film thickness, Innowax, HP)
was used with helium as carrier gas (0.8 mL/min). The GC oven temperature was kept at 60 C
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for 10 min and increased to 220 C at a rate of 4 C/min. This temperature was maintained for 10
min and increased to 240 °C at a rate of 1 °C/min. The injector temperature was set at 250 C.
Mass spectra were recorded at 70 eV with a mass range from m/z 35 to 450. The GC was carried
out using an Agilent 6890N GC system. The temperature of the flame ionization detector (FID)
was 300 C. To obtain the identical elution order with GC-MS, simultaneous auto-injection was
performed on a duplicate of the same column applying the consistent operational conditions
described above. Relative percentage amounts of the separated components were calculated from
FID chromatograms. Identification of the essential oil components was carried out by comparison
of their relative retention times (tR) with those of authentic samples or by comparison of their
relative retention index (RRI) to a series of n-alkanes. Component identification was implemented
by computer matching against commercial databases (Wiley GC/MS Library, Adams Library,
MassFinder 3 Library),43,44 and the in-house “Başer Library of Essential Oil Constituents”
established based on genuine compounds of known essential oils and literature data.45,46 Major
components of pondberry essential oil, i.e. (E)-β-ocimene, (±)-sabinene, (±)-α-phellandrene, (±)limonene, p-cymene, myrcene, and β-caryophyllene were also characterized by comparison of 1H
and 13C NMR chemical shift data with literature data.36,47
Tick Repellent Assay
The tick repellent assay was implemented with reference to previous studies.25,37,48 The A.
americanum nymphs were obtained from a colony at Oklahoma State University, Stillwater, OK
and held at 23–24 °C, ≈97% relative humidity (RH) and a photoperiod of 16 : 8 h [Light phase (L)
: Dark phase (D)].

Test solutions of pondberry extracts were prepared in acetone, (±)-sabinene

and trans-sabinene hydrate were prepared in ethyl acetate. The repellent activity of the test
solutions was evaluated based on the tendency of host-seeking ticks to climb described in detail in
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previous studies.37 Ticks were tested in replicates of 10 ticks per combination of concentration of
pondberry extracts or DEET. The extracts and DEET were tested against five replicates of A.
americanum at 0.827, 0.413, 0.206, 0.103 and 0 (acetone control) mg/cm2 filter paper. Four
replicates of 10 adult I. scapularis ticks each were tested against 0.413 mg pondberry crude extract
/cm2 and two replicates of 10 ticks and one replicate of 11 ticks against the acetone control. Three
replicates of 10 A. americanum nymphs each were tested against 2000 and 0 (ethyl acetate control)
nmole (±)-sabinene and trans-sabinene hydrate/cm2. Tests for repellency differences between
components were conducted using the generalized linear models function of the R software.49 This
permitted modeling of the counts as samples from binomial distributions using the logit link
function. The estimated dose to repel 50% and 95% percent of ticks and approximate 95% fiducial
(inverse regression) confidence limits was estimated using the dose.p function in the package
MASS.50
Fractional Freezing
Four different cold temperature baths (-20, -42, -61, and -200 °C) were generated and high
vacuum (700 mTorr) was applied to fractionate the collected crude essential oil. The four
temperatures were produced by a recirculating chiller (-20 °C), acetonitrile (-42 °C) and
chloroform (-61 °C) cooled by adding dry ice and liquid nitrogen (-200 °C). The temperatures
were maintained by adding coolants every 10 min. Extraction of each collected oil fraction was
completed as described in the Essential Oil Extraction section. GC-MS analysis of the fractions
generated by the fractional freezing was carried out with an HP 6890 series equipped with a
split/splitless capillary injector, an HP 6890 Series injector autosampler, and a DB-5ms column
(30 m × 0.25 mm × 0.25 μm, Agilent). The GC was interfaced to an HP 5973 quadrupole mass
selective detector through a transfer line set at 240 °C. The injector temperature was 220 °C and 1

14

μL injections were performed in the split (1 : 10) mode. The column flow was set at a constant
pressure of 10 psi, providing a nominal initial flow of 1.2 mL/min with helium as carrier gas. The
oven temperature was raised from 60 to 300 °C at a rate of 3 °C/min for a total run time of 80 min.
The filament was operated at 70 eV with an emission current of 35 μA. The multiplier voltage was
automatically set to 2094 V. The ion source and quadrupole temperatures were set with 230 and
120 °C, respectively. The acquisition range was m/z 35–800 at 1.95 scans per second, starting 2.5
min after injection. Components of the four fractions were identified by the identical fashion
delineated in the GC, GC-MS and NMR Analysis of Crude Essential Oil section.
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CHAPTER 2: CONFIGURATIONAL ASSIGNMENTS OF CONFORMATIONALLY
RESTRICTED MEROTERPENOIDS FROM L. MELISSIFOLIA
(The contents of this Chapter were reprinted or modified from the original article published in
Biochim. Biophys. Acta, Gen. Subj. with permission from the publisher via Rightslink® service,
Copyright 2013 Elsevier B.V., Confirmation No. 11305560)
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INTRODUCTION

Endangered plant species are an underutilized source for new chemistry. These discoveries
ironically hold the potential for development into a commercial application that would justify the
conservation of those plant species in jeopardy. This is evidenced by a recent phylogenic analysis
which shows drug producing plant families are concentrated around families which contain
endangered species.51 However, the challenge associated with such limited resources often
prohibits the full elucidation of new structures utilizing conventional techniques such as X-ray
crystallography or spectrometric techniques.

The discovery of new meroterpenoid-based

hydroquinones from a US endangered plant provides a unique opportunity in this regard. Owing
to the conformationally restricted assemblies, investigation of these hydroquinones permits the
demonstration of how quantum mechanical (QM) calculations combined with NMR and electronic
circular dichroism (ECD) studies can assign three dimensional structures in cases where
investigation of such stereochemical detail might not otherwise be feasible due to mass limitations.
The endangered status of L. melissifolia found in the Southeastern US prompted our study
of the plant as an example of how endangered US plants can yield novel chemistry that could
potentially be lost due to extinction. The drupes of L. melissifolia commonly called pondberry
exhibits a dose-dependent tick repellency as discussed in Chapter 1.52 The ethyl acetate extract
of pondberry drupes exerting anti-infective activities was investigated to identify two new
hydroquinone-based meroterpenoid hydroquinones named melissifolianes A (1) and B (2) (Figure
6). The structures of the melissifolianes combine a common 2-(hydroquinone) acetic acid ester
moiety flanked uniquely by two monoterpenoid units in contrast to a single monoterpenoid moiety
as reported in Magnolia denudata.53 The limited amounts of the melissifolianes neither enabled
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assignment of their stereostructure by chemical methods nor facilitated investigation of appropriate
conditions for crystallization. However, the conformationally restricted state, associated with the
acetic ester moiety that bridged hydroquinone and terpenoids moieties, provided the opportunity
to employ computational methods to establish stereochemical details of those meroterpenoids.
Herein, we report the use of NMR and ECD analysis coupled with QM calculations for the full
structural assignment of natural products like the melissifolianes possessing conformationally
restricted moieties.

Figure 6. Structure of melissifolianes A (1) and B (2)
RESULTS AND DISCUSSION
The 1H NMR data of melissifolane A (1) (Table 4) showed resonances for isopropyl-type
methyl protons (δH 0.98, 0.93), two m-coupled aromatic protons (δH 6.58, 6.56), and three allylic
methyls and one methyl group attached to an oxygenated carbon (δH 1.70, 1.33, 1.63, 1.69).
Deshielded methyl protons were observed at δH 3.83, suggesting a methyl ester functional group
which was confirmed by a heteronuclear multiple-bond correlation spectroscopy (HMBC)
correlation between the protons and ester carbonyl at δC 173.4. The 13C NMR resonances deduced
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from the heteronuclear single-quantum correlation spectroscopy (HSQC) spectrum indicated a
benzene ring bearing two oxygenated carbons (δC 148.4, 144.2, 131.2, 117.0, 115.8, 113.3).
Table 4. 1H and 13C NMR data of melissifolianes A and B (1 and 2). The numberings shown in
this Table are corresponding to those in Figure 6.
1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'

1
H (multi, J in Hz)

6.56 (1H, br d, 2.6)
6.58 (1H, br d, 2.4)
3.31, 3.18 (2H, dd, 14.9, 7.5)
5.28 (1H, t, 7.03)
1.69 (3H, s)
2.04 (2H, m)
2.10 (2H, m)
5.12 (1H, t, 5.9)
1.70 (3H, s)
1.62 (3H, s)
4.15 (1H, d, 6.2)
2.28 (1H, ddd, 13.9, 6.1, 2.9)
1.33 (3H, s)
5.80 (1H, d, 9.9 )
5.97 (1H, dd, 9.9, 4.6 )
1.93 (1H, m)
1.63, 1.37 (2H, m)
1.66 (1H, m)
0.93 (3H, d, 6.7)
0.98 (3H, d, 6.5)
3.83 (3H, s)
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1

C
144.2
117.0
113.3
148.4
115.8
131.2
28.3
122.2
136.1
16.2
39.8
26.7
124.4
131.3
25.7
17.7
43.3
35.4
72.3
24.6
131.7
134.0
40.8
23.2
31.7
20.9
21.0
173.4
51.9

2
H (multi, J in Hz)

6.47 (1H, br d, 2.9)
6.57 (1H, br d, 2.7)
3.27 (2H, d, 7.5)
5.30 (1H, t, 7.5)
1.68 (3H, s)
2.05 (2H, m)
2.12 (2H, m)
5.13 (1H, t, 7.6)
1.70 (3H, s)
1.62 (3H, s)
3.98 (1H, dd, 11.3, 6.4)
2.26, 2.19 (2H, m)
4.27 (1H, dd, 10.70, 3.69)
1.77 (3H, s)
5.53 (1H, t, 7.1)
2.79 (2H, t, 6.9)
5.13 (1H, t, 6.8)
1.66 (3H, s)
1.72 (3H, s)
3.77 (3H, s)
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13

C
146.9
118.8
111.3
148.5
115.8
131.3
28.1
121.9
136.4
16.1
39.8
26.7
124.3
131.4
25.7
17.7
42.8
30. 5
79.4
134.0
12.2
126.4
26.7
122.3
132.1
17.8
25.7
174.1
52.2

The inspection of HMBC and double quantum filter-correlation spectroscopy (DQFCOSY) spectra revealed that the gross structure of melissifoliane A (1) was based on a 2(hydroquinone)acetic acid ester moiety flanked by two monoterpenoid units (Figure 7A). The
connectivity between the cyclic terpenoid and 2-(hydroquinone) acetic acid ester groups was
confirmed by the COSY correlation between H-1' (δH 4.15) and H-2' (δH 2.28), and the HMBC
correlations between H-1' and C-8' (δC 23.2), and H-3 (δH 6.56) and C-1' (δC 43.3) (Figure 7A).
The acyclic terpene unit was similarly connected to C-6 of the hydroquinone moiety based on the
COSY correlation of H-7 (δH 3.31, 3.18) and H-8 (δH 5.28), and the HMBC correlations H-8 and
C-6 (δC 131.2), H-7 and C-5 (δC 115.8), and H-7 and C-1 (δC 144.2) (Figure 7A). The
configuration of melissifoliane A (1) was established by utilizing an ensemble of distinctive NMR
chemical shift values, nuclear Overhauser effect (NOE) correlations, and QM calculation. The (E)
C-8–C-9 olefin geometry was assigned based on a characteristic pair of carbon resonances for the
C-10 methyl and the C-11 methylene at δC 16.2 and 39.8, respectively, and NOE correlations

Figure 7. (A) Key HMBC
(arrows) and COSY (bold lines)
and (B) Key NOEs (dotted
lines) of melissifoliane A (1)
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between H2-7 (δH 3.31, 3.18) and H3-10 (δH 1.69), and H-8 (δH 5.28) and H2-11 (δH 2.04) (Figure
7B).
The relative configuration of the hydroxylated monoterpenoid moiety was established
based on the NOE correlations between H-2' (δH 2.28) and H-9' (δH 1.66), H-4' (δH 1.33) and H-9',
and H-8' (δH 1.63, 1.37) and H-9'. 3JH-2',H-8'ax (13.9 Hz) and 3JH-2',H-8'eq values (2.9 Hz) suggested
that the cyclohexene moiety predominantly occupies a half-chair conformation. The orientation of
the isopropyl group was assigned by the NOE correlations between H-11' (δH 0.98) and the methyl
ester group H-13' (δH 3.83). Thus, the relative configuration of the cyclic monoterpenoid unit was
tentatively assigned 2′S*, 3′S*, 7′S*.
The observed 3JH1',H2' value (6.2 Hz) indicated a significant conformational change
associated with the C-1'–C-2' bond, thus indicating that the establishment of C-1' configuration
would be challenging. The NMR and QM combined approach was utilized for the comparison
between experimental and calculated spin-spin coupling constants (SSCCs) to establish the relative
configuration of C-1'. Geometries were optimized in Jaguar (Schrödinger LLC.) using density
functional theory (DFT) at the MPW1PW91/6-31G(d,p) level for all six staggered rotamers
associated with the C-1′–C-2′ bond of diastereomers I and II having different C-1′ configurations
(Figure 8). The SSCCs of each rotamer were calculated using the same theory and basis set in
Gaussian09 (Figure 8, Table 5). To measure experimental homo- and hetero- coupling constants,
O 12'O
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Figure 8. Diastereomers I and II,
the plausible structures of
melissifoliane A (1) with different
C-1' configurations along with the
Newman projections for all
possible staggered rotamers
associated with the C-1'–C-2'
bond

1

H NMR, and heteronuclear long-range coupling (HETLOC) were employed. The total absolute

deviation (TAD)54,55 between the experimental and calculated values (Figure 8, Table 5) verified
that the calculated SSCCs of diastereomer I in Figure 8 with 1′R*, 2′S*, 3′S*, 7′S* showed a better
agreement with the experimental J values.
Table 5. Calculated SSCCs (Hz) of the staggered rotamers of diastereomers I and II shown in
Figure 8 with the experimental values.
Calculated SSCC a
I
3

JH1', H2'

3

a

JH1', C8'

Exp. b

II

g+

g-

anti

g+

g-

anti

3.9

5.0

6.9

4.1

4.1

9.3

6.2

5.9

1.4

4.6

5.3

2.8

1.9

6.5

2

JH1',C2'

-4.6

-1.5

-5.2

-1.8

-3.8

-1.9

-5.0

2

JC1',H2'

-3.9

-4.0

-4.3

-3.3

-3.8

-4.4

-5.0

TAD

4.4

10.8

3.5

8.2

8.2

11.4

b

MPW1PW91/6-31G(d,p) calculated J values. Experimental J values (Exp.) observed from
HETLOC and 1H NMR spectra. TAD values calculated from (Σ|Jcalc - Jexp|). The lowest TAD
values in bold are found in diastereomer I.
The absolute configuration of melissifoliane A (1) was assigned by comparison of the
calculated and experimental ECD spectra.56-63 The major conformers were generated by selecting
dihedral angles for the rotamers associated with the C-6–C-7, C-2–C1', C-1'–C-2', and C-1'–C-12'
bonds. The conformation of the cyclohexene moiety was fixed as a half-chair conformation based
on the coupling constants analysis described above. The Amber* force field was used to define
the initial geometries of generated conformers followed by PM664 semi-empirical optimizations.
These conformers were subsequently used in DFT B3LYP/6-31G(d,p) calculations to obtain more
accurate geometries in the gas phase and in MeCN.65,66 The 24 lowest-energy conformers within
an energy window of 50 kJ/mol (conformers 1–24, for their coordinates see Supplementary Data
2 in the original article67) exhibited different intramolecular hydrogen bond interactions, involving
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the C-1 and C-3' hydroxy groups and the C-12' ester oxygen atoms. Such hydrogen bonding
partially restricted rotation of the C-12'–C-1', C-1'–C-2, and C-1'–C-2' bonds.
The full array of conformers was used for calculations of the excited state in the gas phase
and in MeCN using time-dependent density functional theory (TDDFT). The excitation energies
and rotational strengths of each conformer were Boltzmann-weighted according to the calculated
Gibbs free energies and subsequently fitted to Gaussian 09 (Gaussian Inc.) functions to simulate
ECD curves. The major conformers found at the B3LYP/6-31G(d,p) level were further optimized,
and employed for ECD calculations at the B3LYP/6-311G++(2d,p) level to validate the initial
ECD calculations at the B3LYP/6-31G(d,p) level.

The experimental ECD spectrum of

melissifoliane A (1) shows Cotton effects characteristic of the n → π* electronic transition of the
ester functionality at ca. 300 nm, the 1Lb transition of the aromatic chromophore at ca. 260 nm,
and the 1La transition of the aromatic chromophore in the 220–240 nm region (Figure 9). Figure
9 depicts overlays of the experimental ECD spectrum of melissifoliane A (1), the average
calculated spectrum of the major conformers of melissifoliane A (1) at the B3LYP/6-31G(d,p) and
B3LYP/6-311++G(2d,p) levels, respectively. The calculated ECD data employing the different
Figure
9.
Overlaid
experimental
and
averaged calculated ECD
spectra of melissifoliane
A (1) utilizing the two
difference basis sets
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basis sets shown in Figure 9, taken in conjunction with the experimental ECD curve, was sufficient
to assign the absolute configuration as 1'R, 2'S, 3'S, 7'S.
The 1D NMR data of melissifoliane B (2) (Table 4) resembled those of melissifoliane A
(1), which suggested that it shared structural similarities with the exception of the nature of the
methyl groups of the C-1' substituent. The acyclic terpene and hydroxylated terpenoid moieties
were connected to C-6 (δC 131.3) and C-1' (δC 42.8), respectively, using similar DQF-COSY and
HMBC correlations as described for melissifoliane A (1). The C-8–C-9 olefin geometry was
established as E based on the NOE correlations between H2-7 (δH 3.27) and H3-10 (δH 1.68), and
H-8 (δH 5.30) and H2-11 (δH 2.05). The E geometry of the C-4'–C-6' olefinic bond was assigned
by the chemical shift values of C3' (δC 79.4) and C5' (δC 12.2) and NOE correlations between H35' (δH 1.77) and H2-7' (δH 2.79), and H-3' (δH 4.27) and H-6' (δH 5.53). Melissifoliane B was
optically inactive which suggested a racemic mixture, which was confirmed by chiral
chromatography (Figure 19). The attempt to assign the relative configuration of melissifoliane B
(2) using J-based analysis failed because of the lack of a relevant model for phenyl substituents
and infeasibility in measuring the 3JCH involving quaternary carbons of the hydroquinone moiety.
Consequently, the relative configuration of melissifoliane B (2) was also established employing
the identical manner as for 1.68 The gauche+ conformer associated with C-1′–C-2′ exhibited the
lowest TAD value and this conformer was assembled with the major conformer of the C-2′–C-3′
bond identified by J-based analysis (Figure 10). This collectively elucidated the relative
configuration of melissifoliane B (2) as 1′R* and 3′R*.

CONCLUSIONS
Our study of the Lindera melissifolia metabolome exemplifies how new chemistry remains
undiscovered among the numerous endangered plant species. This also demonstrates how analysis
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by ECD and NMR techniques combined with various QM calculations is a valuable approach to
support the stereochemical assignment of molecules possessing conformationally restricted bonds
linking the different structural moieties. Utilization of the secondary metabolites obtained from
other endangered plant species may serve as added justification for conservation of such plants
given potential socioeconomic value they may generate.

Gauche+ (C-1'–C-2')
Gauche- (C-3'–C-2')
Calcd. SSCC a
Exp. b
Exp. b
3
3
JH1', H(H)
11.3
11
JH(H), H3'
10.7
3
3
JH1', H(L)
3.2
5.2
JH(L), H3'
3.7
3
3
JH1', C3'
2.9
1.5
JH3', C1'
3
2
2
JC1', H(H)
-3
-4
JH(H), C3'
-6
2
2
JC1', H(L)
-3.1
-4
JH(L), C3'
-4
TAD
5.6
Figure 10. The major conformers suggested by QM calculation (C-1′–C-2′, left) and J-based analysis (C2′–C-3′, right). H(H) and H(L) indicate 2.26 and 2.19 ppm, respectively. a SSCCs were calculated at
MPW1PW91/6-31G(d,p). b Experimental J values observed from HETLOC, exclusive COSY (E. COSY),
and 1H NMR spectra. TAD: See Table 5.

EXPERIMENTAL SECTION
General Procedures
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NMR spectra were obtained using a Bruker Avance 400 MHz spectrometer referenced by
residual dichloromethane and chloroform resonances. Homo- and hetero-nuclear coupling
constants were measured using 1H NMR, E. COSY, and HETLOC. Optical rotations were
measured on a Rudolph Autopol V polarimeter. UV-vis spectra were recorded on an Agilent 1100
series diode array and multiple wavelength detectors. The LC-MS analyses were performed using
an Agilent 1100 HPLC system equipped with a Phenomenex Luna 5 m C8(2) column (4.6 × 150
mm), an MeOH/H2O (0.1% HCOOH) gradient solvent system, and a Bruker Daltonics microTOF
mass spectrometer. For chiral chromatography, an Astec Chirobiotic R column (4.6 × 100mm)
was utilized eluting with a 55% MeOH/H2O isocratic solvent condition (20 mM NH4Ac, 35 °C).
HRESIMS spectra were obtained employing a Bruker Daltonics microTOF mass spectrometer
with electrospray ionization. Column chromatography was conducted using silica gel 60 (40–63
m particle size) and reverse phase (RP)-18 (40–63 m particle size). Precoated TLC silica gel 60
F254 plates (Merck) were used for TLC. HPLC was performed on a Waters System equipped with
Waters 2487 dual absorbance detector. Experimental ECD spectrum was acquired at 5 °C with an
Olis CD spectrophotometer. The concentration of the sample was 500 μg/mL in MeCN and the
path length was 5 mm.

Extraction and Purification
For the collection and authentication of the plant material, see Plant Material section in
Chapter 1. The dried ripe drupes of L. melissifolia were coarsely ground and extracted with EtOAc,
and the extract was dried under reduced pressure to give 100 g of crude extract. The extract was
fractionated on silica gel eluted with hexanes-EtOAc (100:0, 80:20, 50:50 and 0:100) and then
with EtOAc-MeOH (80:20, 50:50 and 0:100) to afford 10 fractions, respectively. Fractions 6–9
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exhibited significant anti-infective activities and these active fractions were further
chromatographed by normal phase HPLC [Phenomenex Luna silica, 50 × 250 mm, 10 μm, flow
rate 30 mL/min] with a gradient elution of hexanes-EtOAc (1:0 to 8:2 over 120 min) and, finally,
by RP HPLC [Waters C18 20 × 250 mm, 10 μm, flow rate 10 mL/min; Phenomenex C18 5 × 250
mm, 5 μm, flow rate 1 mL/min] using a gradient elution of H2O-MeOH (1:1 to 0:1 over 110 min)
to obtain the pure compounds.


Melissifoliane A (1)
Melissifoliane A (1, tR = 46 min), a pale yellowish oil, had the molecular formula C29H42O5

deduced from HRESIMS data (obsd [M+Na]+-H2O at m/z 475.2842, calcd [M+Na]+-H2O at m/z
475.2819; obsd [2M+Na]+-H2O at m/z 927.5725, calcd [2M+Na]+-H2O = 927.5751). The specific
rotation ([]23D) was established as +54.0 (c 0.2, MeCN). For 1H and 13C NMR data, see Table 4.


Melissifoliane B (2)
Melissifoliane B (2, tR = 45 min), a pale yellowish oil, had the molecular formula C29H42O5

as deduced from HRESIMS results (obsd [M+Na]+-H2O at m/z 475.2852, calcd [M+Na]+-H2O at
m/z 475. 2819; obsd [2M+Na]+-H2O at m/z 925.5530, calcd [2M+Na]+-H2O =927.5751). For 1H
and 13C NMR data, see Table 4.

QM Computational Calculation
ECD calculation
Initial conformational analysis was conducted using the Amber* force field in the
MacroModel program included in the Schrödinger software package (Schrödinger LLC.). The
resulting structures were optimized using the PM6 semi-empirical method in the Gaussian 09
package (Gaussian Inc.). The PM6-optimized structures were further optimized using DFT gas-
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phase calculations. The geometry optimizations and frequency calculations of the conformers 1–
24 were implemented using the hybrid DFT method B3LYP with the 6-31G(d,p) basis set,
specifying tight convergence. The major conformers (conformers 1, 3, 5, 6, 13, 14, 15, 16, 17 and
19) from the optimization process were further minimized at the B3LYP/6-311++G(2d,p) level
with tight convergence in order to validate the effects of including a larger basis set. Separate
optimizations were carried out starting from the PM6-optimized structures using the conductorlike polarizable continuum solvation model with a dielectric constant representing MeCN. The
excited state calculations were performed using the TDDFT method with B3LYP with each of the
two basis sets [i.e., 6-31G(d,p) and 6-311++G(2d,p)]. The generated excitation energies and
rotational strengths were weighted using Boltzmann averaging based on the calculated Gibbs free
energy of each conformer and then fitted with a Gaussian function to generate the computed ECD
spectra. These raw computed data were visualized utilizing SpecDis69 for comparison to the
experimental ECD spectrum.

SSCC calculation
Geometries were optimized in Jaguar (Schrödinger LLC.) using DFT at the
MPW1PW91/6-31G(d,p) level for all six staggered rotamers of each diastereomer associated with
C-1'–C-2' of melissifolianes A and B (1 and 2). The SSCC of each rotamer was calculated using
the same theory and basis set in Gaussian09.70 The total absolute deviation (TAD)54,55 between
experimental and calculated values was used to suggest the most relevant conformers.
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Figure 11. 1H NMR (top) and DQF-COSY (bottom) spectra of melissifoliane A (1)
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Figure 12. HSQC (top) and HMBC (bottom) spectra of melissifoliane A (1)
30

Figure 13. NOESY (top) and HETLOC (bottom) spectra of melissifoliane A (1)
31

Figure 14. HRESIMS spectrum of melissifoliane A (1)
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Figure 15 . 1H NMR (top) and DQF-COSY (bottom) spectra of melissifoliane B (2)
33

Figure 16. HSQC (top) and HMBC (bottom) spectra of melissifoliane B (2)
34

Figure 17. NOESY (top) and E.COSY (bottom) spectra of melissifoliane B (2)
35

Figure 18. TOCSY (top) and HETLOC (bottom) spectra of melissifoliane B (2)
36

Figure 19. The RP chromatogram (Phenomenex C8 5 × 150 mm, 5 μm, flow rate 0.6 mL/min
using an isocratic elution of 70% MeOH in H2O) (top) and chiral chromatogram (Astec Chirobiotic
R 4.6 × 100mm, 5 μm, flow rate 0.6 mL/min with an isocratic elution of 55% MeOH in 20 mM
NH4Ac, pH 6, 35 °C) (bottom) of melissifoliane B (2)
37

Figure 20. HRESIMS spectrum of melissifoliane B (2)
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CHAPTER 3: DISCOVERY OF DRUG LEADS FOR TREATMENT OF SEPSIS FROM
THE KOREAN ENDANGERED SPECIES RHODODENDRON BRACHYCARPUM
(The contents of this chapter were reproduced or edited from the original article published in
Biochim. Biophys. Acta, Gen. Subj. with permission from the publisher via Rightslink® service,
Copyright 2014 Elsevier B.V., Confirmation No. 11305580)
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INTRODUCTION

Endangered plant species are an important resource for exploring novel drug prototypes71
as discussed in the previous chapters. Rhododendron brachycarpum G. Don (Ericaceae) is a broadleaved shrub native to northern Korean and central Japan.72 The numbers of this species have been
drastically diminished due to climate change, leading to its classification as an endangered and
rare species in Korea.72 Although R. brachycarpum is traditionally employed in the treatment of
diseases including cardiovascular, diabetes, hypertension, hepatitis, rheumatoid arthritis, and
headache,73 only a limited number of studies have been carried out to validate these
ethnopharmacological uses.74,75
Sepsis is a systemic and overwhelming inflammatory response of an organism to a local
infection, potentially progressing to severe sepsis and septic shock with multiple organ failure and
hypotension.76 The mortality associated with the disease is as high as 50–70%, leading to its
designation as the number one cause of death in intensive care units worldwide.76 Comprehensive
anti-inflammatory treatments have not alleviated the disease phenotypes during the last few
decades.76 The only FDA-approved antiseptic drug drotrecogin alfa (Xigris®) was withdrawn from
the market due to its questionable efficacy,77 thus stressing the necessity for the search of potential
antiseptic prototypes with a novel mode of action (MOA). Among the therapeutic strategies
targeting the mitigation of sepsis,76 enhancement of the integrity of endothelial cells (ECs) has
emerged as a sensible MOA for treatment of the serious disease.78,79 Disruption of the integrity of
ECs facilitates leucocytes to access inflamed tissue and hence initiating such vascular
inflammatory manifestations.78,79 In this regard, high mobility group box 1 (HMGB1) protein
could be targeted specifically for the exploration of novel antiseptic agents capable of achieving
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vascular barrier augmentation because of the significant role of the protein in disturbing the barrier
integrity of ECs, and ultimately inducing severe sepsis and related fatalities.78-80
In continuing efforts aimed at discovering viable and new drug prototypes from endangered
species,71-73,81 the isolation and structural characterization of rhododendroside A (1), the first
bicyclic megastigmane glycoside, is elaborated herein. It is also discussed whether this scaffold
can be developed into a septic drug lead capable of mitigating HMGB1-induced vascular
disruption.

RESULTS AND DISCUSSION
An extract of the leaves of R. brachycarpum was fractionated and purified employing
various chromatographic techniques, leading to the purification of megastigmane glucosides (1–
5) (Figure 21. (A) Structures of 1–5 from R. brachycarpum and (B) key COSY (▬) and HMBC
(→) correlations in 1). Compound 1 was obtained as a yellow amorphous powder and the
molecular formula was established as C19H32O8 based on HRESIMS and

13

C NMR data (obsd

[M+Na]+ at m/z 411.1996, calcd [M+Na]+ at m/z 411.1995). The 1H NMR spectrum (Table 6)
displayed resonances for an olefinic proton (δH 4.51), an anomeric proton (δH 4.43), an oxymethine
proton (δH 4.16), an allylic (δH 1.66) and two tertiary and one oxygenated secondary methyl groups
(δH 1.30, 1.07, 1.03). The
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C NMR spectrum (Table 6) exhibited 19 resonances including six

carbon resonances belonging to a glucopyranosyl moiety (δC 102.8, 75.1, 78.0, 71.6, 77.8, 62.7),
two olefinic carbons (δC 149.4, 97.6), an oxymethine carbon (δC 73.2), one quaternary and two
oxygenated tertiary carbons (δC 81.5, 72.0, 40.7), three methylene carbons (δC 44.7, 41.4, 29.9),
one allylic (δC 20.0), and two tertiary and one oxygenated secondary methyl carbons (δC 27.4,
24.6, 22.7). These spectroscopic data are similar to those of icariside B2 (3),82 indicating the
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presence of a megastigmane glucoside framework in 1. Differences in the NMR data of 3 and 1
include the disappearance of the proton signals of the conjugated trans-olefinic group and a change
of the nature of the acetyl methyl group in 3 compared to 1. These differences are compatible with
a structure of 1 generated from 3 via cyclization of the C-6 methyl vinyl ketocarbonyl functionality
onto the oxirane moiety. This was confirmed by HMBC correlations between H-8 (δH 4.51) and
C-6 (δC 72.0), C-7 (δC 29.9), C-9 (δC 149.4), and C-10 (δC 20.0), and between H-7 (δH 2.34, 1.99)
and C-6 (δC 72.0), C-8 (δC 97.6), and C-9 (δC 149.4) (Figure 21). Such formation of a hexahydro4H-chromene moiety leads to a unique cyclomegastigmane scaffold, which has not previously
been observed in bisnorsesquiterpenoids. The connectivity of the aglycone and monosaccharide
moieties was confirmed by an HMBC correlation between H-1' (δH 4.43) and C-3 (δC 73.2) (Figure
21). The coupling constant (J = 7.8 Hz) of the anomeric proton confirmed a β-glucosidic linkage.
Acid hydrolysis followed by GC analysis confirmed the presence of D-(+)-glucose.

Figure 21. (A) Structures of 1–5 from R. brachycarpum and (B) key COSY (▬) and HMBC (→)
correlations in 1
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Table 6. 1H and 13C NMR data (Exp.) of compound 1 in methanol-d4 and calculated chemical
shift values (Cal.) of diastereomers I and III
1

position a
1
2ax.

1.76, t, (12.6)
1.60, ddd,
(12.6, 4.1, 2.4)
4.16, tt, (12.6, 4.1)
1.82, dd, (13 b.2, 12.6)
2.12, ddd, (13.2, 4.1, 2.4)

2eq.
3
4ax.
4eq.
5
6
7α
7β
8
9

a

H NMR chemical shift values (δH)
Exp.
δH, multi, (J in Hz)
Ib

1.99, m
2.34, m
4.51, m

10

1.66, m

11

1.03, s

12

1.07, s

13

1.30, s

1′
2′
3′
4′
5′
6′a
6'b
DP4 (%)

4.43, d, (7.8)
3.18, dd, (9.1, 7.8)
3.39, m
3.35, m
3.35, m
3.90, dd, (11.9, 2.1)
3.73, dd, (11.9, 5.1)
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Cal.
IIIc

1.90

1.75

1.59

1.50

4.35
1.84
2.07

4.33
2.03
2.19

1.99
2.25
4.61

1.94
2.31
4.60

1.68
1.77
1.54
0.94
0.97
0.96
1.19
1.46
0.68
0.89
1.63
1.49
4.54
3.51
3.74
3.60
3.51
4.08
3.83
96.3

1.58
1.73
1.66
1.06
1.27
0.66
0.61
1.59
1.17
1.60
0.98
1.32
4.50
3.51
3.73
3.56
3.51
4.09
3.83
3.7

C NMR chemical shift values (δC)
Cal.
Exp.
Ib
III c
40.7
44.8
44.5
44.7
47.7
45.7
73.2
41.4

68.6
44.4

69.0
46.6

81.5
72.0
29.9

82.4
75.7
33.5

82.6
75.7
33.9

97.6
149.4

96.5
146.6

96.5
146.8

20.0

21.0

21.0

27.4

28.0

28.2

24.6

25.2

25.3

22.7

25.2

24.8

102.8
75.1
78.0
71.6
77.8
62.7

103.9
76.5
78.1
72.3
77.8
64.9

104.1
76.6
78.2
72.2
78.2
65.0

70.9

29.1

See Figure 21. b,c Calculated chemical shift values for diastereomers I and III shown in Figure 22

The relative configuration of the aglycone was established via coupling constants and NOE
correlations. The coupling constants of H-3 (tt, 12.6, 4.1 Hz) suggest that the cyclohexane ring
occupies either a chair or boat conformation. The relative configuration of C-5 was assigned based
on the presence of a strong NOE correlation between H-3 (δH 4.16) and H-12 (δH 1.07) and the
absence of an NOE correlation between H-3 (δH 4.16) and H-13 (δH 1.30) (Figure 22). Based on
these findings, two plausible diastereomers (diastereomer I: 3S, 5R, 6R; diastereomer II: 3S, 5R,
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6S) were proposed and minimized with the aforementioned conformational dihedral constraints
and spatial distance information employing the MMFF94 force field (Schrödinger LLC.) (Figure
22A). The presence of an NOE correlation between H-12 (δH 1.07) and H-8 (δH 4.51) in
diastereomer I and the absence of an NOE correlation between H-11 (δH 1.03) and H-13 (δH 1.30),
but feasible in diastereomer II, support the relative configuration of diastereomer I and confirm its
structural equivalence with compound 1 (Figure 22A). Owing to the mass limitations of 1,
definition of the absolute configuration was attempted utilizing GIAO NMR chemical shift
calculations with accuracy improved by application of DP4 analysis that has been successfully
applied for investigation of stereochemical details.83-85 Having established the D-glucopyranosyl
moiety in 1, diastereomers I and III with enantiomeric aglycone moieties were considered (Figure
22). The major conformers of diastereomers I and III, generated by conformational searches
employing Macromodel (Schrodinger LLC.), were subjected to gauge-invariant atomic orbital
(GIAO) shielding constant calculations at the B3LYP/6-31G(d,p) level employing the Gaussian
09 package (Gaussian Inc.).

Figure 22. (A) Minimized stereostructures of plausible diastereomers of 1 (yellow dotted lines
indicate NOE correlations) and (B) their 2D representations
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The calculated chemical shift values were Boltzmann-averaged based on their relative
MMFF94 potential energy and these averaged values were used for the calculation of DP4
probability. According to DP4 analysis (Table 6), Diastereomer I was supported with 98.4%
probability when chemical shift values of the two nuclei were taken into consideration, permitting
assignment of absolute configuration of compound 1 identical to that showed for Diastereomer I.
Moreover, consistency regarding the 3S-configuration among analogues 2–582,86,87 further supports
the DP4 prediction of the 3S configuration of 1 when considered in conjunction with a similar
biosynthetic pathway towards these bisnorsesquiterpenes. As shown in Figure 23, enzymatic
epoxidation of 5 would stereochemically be directed by the 3β-equatorial substituent, leading to
formation of oxirane 6 that would be susceptible to successive cyclization and dehydration via 7
to form 1. On the basis of these findings, the structure of 1 was defined as (3S,5R,6R)-1,1,5,9tetramethyl-3-β-D-glucopyranosyloxy-2,3,4,5-tetrahydro-7H-chromen-6-ol,

named

rhododendroside A (1). The known megastigmane glucosides, picrionoside A (2),86 icariside B2
(3),82 citroside A (4),87 and icariside B6 (5)82 were identified by 1D and 2D NMR analysis and
confirmed by comparing the physical and spectroscopic data with those in the literature.

Figure 23. Plausible biosynthetic pathway for generation of rhododendroside A (1)
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Compounds 1–5 were evaluated for their potential to hamper HMGB1-mediated vascular
disruption as a cause of severe sepsis and associated manifestations.78,79,88 To evaluate actin
cytoskeletal arrangement activity of 1–5, human umbilical vein endothelial cells (HUVECs) were
treated with 10 μM of each compound employing immunofluorescence staining of HUVEC
monolayers with the F-actin labeled fluorescein phalloidin (Figure 24A). The control displayed
random F-actin distribution throughout cells with actin filament bundles localized at cell
boundaries (Figure 24A) while vascular barrier disruption triggered by HMGB1 (1 μg/mL) was
evidenced by the generation of paracellular gaps upon HMGB1 treatment (arrowed in Figure
24A). Pretreatment with 1, 2, and 5 eliminated HMGB1-induced paracellular gaps and facilitated
the formation of dense F-actin rings (Figure 24A), protecting vascular barrier integrity from
HMGB1-induced vascular stress. However, pretreatment with 3 and 4 did not recover the
HMGB1-mediated paracellular gaps (Figure 24A). To further examine if compounds 1–5 enhance
barrier integrity of HUVECs, a permeability assay was performed with various concentrations (1–
10 μM). Pretreatment with 1, 2, and 5 (10 μM) restored the levels of permeability to those of the
negative control (Figure 24B) in HMGB1-stimulated barrier integrity disruption while their
pretreatment (10 μM) without the vascular stressor did not influence the barrier integrity,
validating their strong supportive action of vascular barrier integrity (Figure 24B). To verify if the
observed barrier protective action was associated with HMGB1 signaling through its receptors,
expression of the associated receptors including toll-like receptors 2 and 4 (TLR2, TLR4) and
receptor for advanced glycan endproducts (RAGE) was monitored upon pretreatment with
compounds 1–5 (1–10 μM). Pretreatment of HUVECs with 1, 2 and 5, diminished the HMGB1
receptors in a dose-dependent manner, implying that the active compounds exerted the vascular
barrier restorative action via the inhibition of HMGB1 interacting with the receptors (Figure 24C).
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Phosphorylation of p38 mitogen-activated protein kinase (MAPK) was also evaluated employing
enzyme-linked immunosorbent assay (ELISA) based on studies validating HMGB1 induces proinflammatory response by promoting phosphorylation of p38.78,79 The treatment of HUVECs with
HMGB1 significantly enhanced phosphorylation of p38 and this up-regulation was attenuated
upon the pretreatment with 1, 2, and 5, indicating that they averted HMGB1-induced proinflammatory reactions and consequently maintaining vascular barrier integrity (Figure 24D).
Overall, these in vitro findings cohesively corroborated the active compounds exerted vascular
protective potential via inhibition of HMGB1-induced pro- inflammatory response.
In vivo experiments employing murine models were conducted to confirm the observed in
vitro vascular barrier protective effects of the examined compounds. Intravenous pretreatment of
mice with 1–5 (7.7 μg/mouse) was carried out followed by HMGB1 [2 μg/mouse, intravenous
(i.v.)]-induced barrier disruption in vivo. Compounds 1, 2, and 5, protecting vascular barrier
integrity in vitro, also restored vascular permeability in vivo upon HMGB1-induced proinflammatory stimuli based on the decreased dye leakage levels to near those of the negative
control, while compounds 3 and 4 did not suppress the levels of dye leakage (Figure 24A). To
corroborate in vitro anti-permeability effects of the active compounds, in vivo leukocyte migration
was evaluated by counting the number of migrated leukocytes into peritoneal cavities upon
HMGB1-challeged mice models. As shown in Figure 25B, i.v. pretreatment with 1, 2, and 5
inhibited migration of leukocytes based on the decreased peritoneal leukocytes counts, verifying
their inhibitory action on leukocytes chemotaxis upon HMGB1-induced inflammatory
environment.
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Figure 24. In vitro evaluation of vascular protective action of compounds 1, 2, and 5 against HMGB1
(1 μg/mL for 16 h)-induced vascular barrier disruption. Data were analyzed upon pretreatment of
HUVECs with the indicated concentrations for 6 h. (A) Staining for F-actin upon pretreatment of 1–5.
(B) HMGB1-induced permeability was monitored by assessing the flux of Evans blue bound albumin
across HUVECs. (C) Influence of 1, 2, and 5 on expression of HMGB1 receptors, and (D)
phosphorylation of p38 was evaluated by ELISA. (C) White, gray, and black bars indicate expression
of TLR2, TLR4, and RAGE. Results are indicated with the means ± standard deviations (SDs) of
different of at least three experiments and *p < 0.05 and **p < 0.01 compared to cells only treated with
HMGB1 (B–D).
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To validate if the active megastigmane glucosides may be developed into practical
prodrugs for treatment of septic fatalities, they were administered to mice (7.7 μg/mouse) upon
cecal ligation and puncture (CLP) operation employed to simulate the late stage of severe sepsis.89
According to the Kaplan–Meier survival analysis,78,79 compounds 1, 2, and 5, demonstrating potent
vascular barrier protective activity in vitro and in vivo, improved the survival rate to 60, 40, and
40%, respectively, 132 h after the CLP operation (Figure 25C). In view of these biological findings,
it is plausible that the megastigmane glucosides restore in vitro and in vivo vascular integrity with
mitigating HMGB1-induced pro-inflammatory vascular stimuli, ultimately leading to alleviating
septic lethality. Thus, megastigmane
glucosides (1, 2 and 5) could be a sensible
starting point not only for conducting
further

structure-activity

relationship

studies but also developing an effective
septic agent capable of inhibiting HMGB1.
Figure 25. (A, B) In vivo vascular
supportive and antiseptic action of 1–5 (7.7
μg/mL) upon HMGB1 (2 μg/mouse, i.v.)mediated pro-inflammatory environment
and (C) CLP operation. Effects of 1–5 on
vascular permeability were measured by the
amount of Evans blue in peritoneal
washings (n=5). (A) H and D stand for mice
groups administered with HMGB1 and
DMSO, respectively. (B) Anti-migration
potential (n=5) of 1–5 was evaluated by
counting the number of migrated leukocytes
into peritoneal cavities. (C) Anti-lethality
activity (n=10) of those compounds was
assessed using a CLP-induced septic shock
mice model. Control CLP mice (●) and
sham-operated mice (○) were administered
sterile saline and survival was monitored
every six-hour. Results are shown with the
means ± SDs of three different experiments
and *p < 0.05 and **p < 0.01 compared to
mice only treated with HMGB1 (A,B).

49

CONCLUSION
This Chapter delineates that R. brachycarpum may be the source of a unique scaffold that
can be developed into an antiseptic lead mitigating HMGB1-induced vascular pro-inflammatory
stimuli. These results also reaffirm that rare and endangered plant species offer unique
opportunities to explore novel drug leads, warranting conservation efforts especially in cases
where modern-day disease challenges are intensifying.

EXPERIMENTAL SECTION
General Experiments
NMR experiments were conducted using a Bruker DMX 250 and Bruker DMX 600
spectrometers (Karlsruhe, Germany) referenced by residual pyridine and methanol signals.
Specific rotations were recorded using a JASCO DIP-1000 (Tokyo, Japan) and mass spectrometric
data were obtained utilizing a SYNAPT G2 Waters mass spectrometer (Manchester, U.K.).
Medium-pressure liquid chromatography (MPLC) was carried out employing Biotage IsoleraTM
RP C18 SNAP Cartridge KP-C18-HS and normal-phase SNAP Cartridge KP-Sil (340 g, Biotage
AB, Uppsala, Sweden). The GC analysis was carried out on a Shimadzu-2010 with an SPB-1
column (0.25 mm × 30 m, temperature: 250 ˚C) employing FID and helium as carrier gas. HPLC
separation was performed using a Gilson system with a UV detector and Phenomenex Luna C18
column (250 × 21.2 mm, 10 μm and 250× 4.60 mm, 5 μm). TLC was performed on glass plates
precoated with silica gel 60 F254 and RP-18 F254 (Merck). Column chromatography was carried out
using silica gel (Merck, 70 – 230 mesh).

Extraction and purification
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Leaves of R. brachycarpum were purchased from a farm in Gongju Korea in 2011,
identified by Prof. MinKyun Na (College of Pharmacy, Chungnam National University), and
deposited at the Pharmacognosy Laboratory of the College of Pharmacy, Chungnam National
University, Daejeon, Korea (CNU00195). Dried leaves (25 kg) were extracted with MeOH (2 ×
250 L) at room temperature for one week and the extract was concentrated to yield a brownish
slurry (6 kg). Half of the extract (3 kg) was suspended in H2O (10 L) and partitioned three times
with n-hexane (10 L), CHCl3 (10 L), EtOAc (10 L), and BuOH (10 L) to afford four extracts
amounting to 438, 140, 450, and 320 g, respectively. The BuOH-fraction (320 g) was further
subjected to silica gel column VLC and eluted with CH2Cl2:MeOH:H2O (10:1→2:1:0.1) to obtain
six fractions (Fr. B1–B6). Fr. B1 (10 g) was purified by MPLC (C18 SNAP Cartridge KP- C18-HS,
340 g) eluting with MeOH:H2O (3:7 → 7:3) to afford seven sub-fractions (Fr. B11–B17). Fr. B14
(1.46 g) was further purified employing preparative HPLC (Luna C18 column: 250 × 21.20 mm,
20% MeCN, flow rate: 6 mL/min) to afford compounds 2 (26 mg, tR 40.2 min) and 5 (3.8 mg, tR
53.6 min). Fr. B2 (22 g) was fractionated into nine fractions (B21–B29) utilizing MPLC (C18
SNAP Cartridge KP-C18-HS, 340 g) eluting with acetone:MeOH:H2O (0:0:100→12:28:60). Fr.
B26 (1.7 g) was subjected to silica gel MPLC (SNAP Cartridge KP-Sil, 120 g) and eluted with
EtOAc:MeOH (98:2→90:10) to yield five fractions (B261–B265). Fr. B262 (92 mg) was
chromatographed over a silica gel column (2 × 80 cm) and eluted with CHCl3:acetone:H2O
(1:2:0.1) to obtain compound 1 (2 mg). Compound 4 (34 mg) was acquired from Fr. B264 (120
mg) using a silica gel column (2 × 80 cm) eluting with CHCl3:MeOH:H2O (6.5:1:0.1). Fr. B27 (2
g) was subjected to silica gel MPLC (SNAP Cartridge KP-Sil, 120 g) and eluted with
CHCl3:MeOH (94:6→85:15) to yield compound 3 (159 mg).
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Rhododendroside A (1)
Rhododendroside A (1): yellow amorphous powder; [α] 20D = -15.4 (c 0.1, MeOH);

HRESIMS (obsd [M+Na]+ at m/z 411.1996, calcd [M+Na]+ at m/z 411.1995). 1H NMR (methanold4, 600 MHz) and

13

C NMR (methanol-d4, 150 MHz) data, see Table 6. With reference to a

previous study,90 the acid hydrolysis of compound 1 was performed as follows; the compound was
heated in 10% HCl (1 mL) at 85 ˚C for 3 h and the residue was partitioned with EtOAc and H2O.
The aqueous layer was evaporated to yield a residue and the residue was dissolved in anhydrous
pyridine (100 μL) followed by the addition of 0.1 M L-cysteine methyl ester hydrochloride (100
μL). After heating at 60 ˚C for 1.5 h, the residue was dried and trimethylsilylated with the addition
of 1-trimethylsilylimidazole solution (500 μL), and heated at 60 ˚C for 5 min. The dried product
was partitioned with n-hexane and H2O, and the non-polar layer was analyzed using GC. The
monosaccharide moiety was confirmed as D-glucose based on comparison of the retention time
with that of a D-glucose standard (tR 16.21 min) (Figure 30).

GIAO NMR chemical shift calculations83,84
All conformational searches were achieved employing Macromodel (Version 9.9,
Schrodinger LLC.) program with “Mixed torsional/Low Mode sampling” in the MMFF force field.
The searches were performed in the gas phase with a 50 kJ/mol energy window limit and 10,000
maximum number of steps to completely investigate all low-energy conformers. All minimization
processes were accomplished utilizing polak-ribiere conjugate gradient (PRCG) method, 10,000
maximum iterations, and a 0.001 kJ (mol Å)−1 convergence threshold. C-2–C-3 and C-3–C-4
bonds in compound 1 were constrained using a 1,000 force constant based on the associated
coupling constants [3JH-2ax,H-3 (12.6 Hz), 3J H-3,H-4ax (12.6 Hz)]. Conformers within 10 kJ/mol of
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each global minimum of the two diastereomers (diastereomers I and III shown in Figure 22) were
selected for GIAO shielding constants calculation without geometry optimization employing
Gaussian 09 package (Gaussian Inc.) at the B3LYP/6-31G(d,p) level in the gas phase. Calculated
x
chemical shift values were obtained according to the following equation: δcalcd
= (σ0 – σx)/(1 –

σ0/106) in which δcalcd is the calculated chemical shift value for nucleus x (e.g., 1H or 13C), ߪ ௫ and
x

ߪ  are the calculated isotropic constants for nucleus x and tetramethylsilane (TMS), respectively.
The geometry of TMS was optimized utilizing the B3LYP/6-31G(d,p) level in the gas phase for
unbiased comparison of calculated chemical shift values with those of other molecules according
to the original authors’ recommendation.84 These calculated chemical shift values were
Boltzmann-averaged based on their relative MMFF94 potential energy and these averaged values
were used for the calculation of DP4 probability employing an applet available at http://wwwjmg.ch.cam.ac.uk/tools/nmr/DP4/. All 3D images in this Chapter were rendered utilizing Pymol
1.6.x (Schrödinger LLC.).

53

11

12

OH
1

O
1'

O
6'

OH

7

6

4

OH

O

10

13

OH
OH

Figure 26. 1H NMR (top) and 13C NMR (bottom) spectra of rhododendroside A (1)
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Figure 27. COSY (top) and HSQC (bottom) spectra of rhododendroside A (1)
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Figure 28. HMBC (top) and NOESY (bottom) spectra of rhododendroside A (1)
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Figure 29. HRESIMS spectrum of rhododendroside A (1)
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GC chromatogram of standard D-glucose (retention time: 16.38 min)

GC chromatogram of standard L-glucose (retention time: 17.70 min)

GC chromatogram of the glucose obtained from hydrolysis of rhododendroside A (1)
(retention time: 16.21 min)
Figure 30. Identification of the glucose moiety in rhododendroside A (1) employing acid
hydrolysis followed by GC analysis
58

CHAPTER 4: SCRUTINY OF THE SOUTH AMERICAN ENDANGERED SPECIES
DIPLOSTEPHIUM RHODODENDROIDES FOR ANTIDIABETIC DRUG LEADS
CAPABLE OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B
(Some contents and figures in this chapter were reprinted from the original article published in
Proc. Nat. Acad. Sci. U.S.A. with an appropriate citation. Permission requests have not been
made based on the publisher policy item No. 3)
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INTRODUCTION

The genus Diplostephium comprising ~110 species is a member of the Asteraceae family,
one of the drug-producing families addressed in the aforementioned chapters. Previous studies on
species in the genus Diplostephium have revealed the presence of only a few chemical constituents
including diterpenoids, diterpene lactones, phenylpropanoids,91,92 and flavonoids.93 This implies
that the genus may be an untapped resource for providing prodrug leads. The species D.
rhododendroides Hieron. is a rare South American shrub native to the Andes and found at altitudes
of 3000 – 4500 meter.94,95 The genus Diplostephium is classified into three principal types based
on the shapes of disk flowers96 and D. rhododendroides belongs to one of those types featured with
club-shaped disk flowers merely divided into two equal lobes.
Globally, elevated incidence of type 2 diabetes mellitus and obesity has prompted the
search for new drug leads to alleviate metabolic diseases. Resistance to insulin and leptin is
regarded as a common phenotype of type 2 diabetes mellitus and its related metabolic disorders.97
In this regard, inhibition of protein tyrosine phosphatase 1B (PTP1B) has been regarded as a
sensible approach to treat these metabolic manifestations. According to a previous study, PTP1B
knock-out murine models demonstrated the reduced circulation of insulin, glucose, and
triglyceride levels upon intravenous injection of insulin.98,99 This phosphatase is comprised of 435
amino acids and the residues 177-185 construct a flexible loop called “WPD loop”. This loop is
activated via its conformational change from “open” (inactivated) to “closed” (activated) upon
substrate binding, leading to the formation of a tight binding pocket for the dephosphorylation
catalytic reaction.100 Wiesmann et al.101 discovered a novel allosteric binding site ~20 Å away from
the catalytic pocket in PTP1B and formulated several allosteric inhibitors capable of stabilizing
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the inactivated open conformation, which thereby hampering the closure of the WPD loop. Owing
to this allosteric binding site being poorly conserved among allosteric binding sites in other
phosphatases, a specific inhibitor binding to the allosteric site of PTP1B may be developed into a
highly selective antidiabetic agent. This is verified by the selective noncompetitive PTP1B
inhibitor trodusquemine (MSI-1436) that has been advanced to phase I clinical trials as a potent
hypoglycemic prodrug.101,102
Computational approaches using a wealth of PTP1B crystal structures (~100)103 have been
a crucial avenue for rational design and/or exploration of potent inhibitors104-107 and successfully
applied to the identification of an oxalylaminobenzoic acid moiety as a competitive inhibitor of
PTP1B.106,107 In particular, MD simulation could be an effective tool to search for PTP1B
antagonists because the technique permits the investigation of dynamic changes of the WPD loop
motility upon binding events.104,108,109
As a follow-up study of previous research on D. rhododendroides,71 this chapter presents
details of the isolation and structure elucidation of diplostephiosides A (1) and B (2) and their
evaluation for PTP1B inhibitory potential. To expand a previous docking study,71 molecular
dynamics (MD) trajectory simulation was implemented for investigation of the conformational
state changes of the WPD loop upon allosteric binding simulation of 1, 2, and the Wiesmann’s
allosteric inhibitor.101

RESULTS AND DISCUSSION
The molecular formula of diplostephioside A (1) was established as C26H32O13 based on
information gleaned from a sodium adduct ion at m/z 575.1694 [M + Na]+ in HRESIMS and 13C
NMR data (Table 7).71 The 1H and 13C NMR data of 1 (Table 7) exhibited the presence of two
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symmetrical tetrasubstituted benzenoid moieties [δH 7.61 (H-2′, 6′), 6.85 (H-2, 6) and δC 154.4 (C3, 5), 149.1 (C-3′, 5′), 143.9 (C-4′), 135.8 (C-4), 134.5 (C-1), 120.1 (C-1′), 108.6 (C-2′, 6′), 105.6
(C-2, 6)], a glucopyranosyl moiety [δH 5.75 (H-1′′) and δC 105.1 (C-1′′), 78.6 (C-2′′), 76.2 (C-4′′,
5′′), 72.2 (C-3′′), 65.4 (C-6′′)], an ester carbonyl carbon [δC 167.1 (C-7′′)], and an E-configured
olefinic moiety [δH 6.84 (H-7, d, J = 15.6 Hz), 6.60 (H-8, dt, J = 15.6, 4.8 Hz) and δC 129.8 (C-7),
131.4 (C-8)].71 The HMBC correlations between the proton resonances at δH 7.61 (H-2′, 6′) and
the ester carbonyl carbon at δC 167.1 (C-7′′) as well as between the 3′- and 5′-methoxy protons at
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δH 3.74 and C-3′ and 5′ at δC 149.1 revealed the presence of a syringoyl moiety (Figure 31B).71
The second 1,2,3,5-tetrasubstituted aromatic moiety was determined to be part of the sinapyl
alcohol unit on the basis of the HMBC correlations from the oxymethylene proton resonances at
δH 4.59 (H2-9) to the olefinic carbon resonances at δC 131.4 (C-8) and 129.8 (C-7), from the olefinic
proton resonances at δH 6.84 (H-7) and 6.60 (H-8) to the aromatic carbon resonances at δC 134.5
(C-1) and 105.6 (C-2), and from the C-3 and C-5 methoxy proton resonances at δH 3.77 to the
aromatic carbon resonances at δC 154.4 (C-3, 5) (Figure 31B).71 The syringoyl, sinapyl alcohol,

(A)

(B)

Figure 31. (A) Secondary metabolites from D. rhododendroides (1–4) and (B) Key HMBC (→)
correlations for diplostephiosides A (1) and B (2)
63

and glucosyl moieties were connected based on HMBC correlations (Figure 31B).71 The
correlation from the anomeric proton resonance at δH 5.75 (H-1′′) to the carbon resonance at δC
135.8 (C-4) indicated the acetalic linkage between C-1′′ of glucose and C-4 of the sinapyl alcohol
moiety. In addition, the deshielded resonances for the diastereotopic C-6′′ protons of glucose at δH
5.22 and 4.97, and the carbon at δC 65.4 implied an ester linkage between C-6′′ of the
glucopyranosyl moiety and the ester carbonyl of the syringoyl moiety. This was confirmed by the
HMBC correlation from the glucosyl C-6′′ methylene proton resonances at δH 4.97 and 5.22 to
the carbonyl carbon resonance of the syringoyl moiety at δC 167.1 (C-7′′) (Figure 31B).71 The
coupling constant of the anomeric proton (H-1′′, d, J = 7.2 Hz) confirmed a β-configured glucosidic
linkage. Acid hydrolysis followed by GC analysis of the trimethylsilylated derivative confirmed
the presence of the D-(+)-glucopyranosyl moiety in 1 (Figure 37). Thus, the structure of the
compound 1, diplostephioside A, was assigned as 4-[6-O-(4-hydroxy-3,5-dimethoxy-benzoyl)-βD-glucopyranosyloxy]-3,5-dimethoxyphenylprop-7E-en-9-ol]

based

upon

proper

phenylpropanoid numbering and nomenclature in contrast to those followed in reference 71.
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Table 7. NMR data of diplostephiosides A (1) (pyridine-d5) and B (2) (methanol-d4)
1
δC

b

δH, mult. (J in Hz)

δC

1

134.5

2

105.6

3

154.4

153.4

4

135.8

136.8

5

154.4

6

a

2
δH, mult. (J in Hz)

130.5
6.85 a, s

106.1

6.80, s

153.4
a

105.6

6.85 , s
a

106.1

6.80, s

7

129.8

6.84 , d (15.6)

153.5

7.42, d (16.0)

8

131.4

6.60, dt (15.6, 4.8)

127.6

6.65, dd (16.0, 7.6)

9

63.2

4.59, br d (4.8)

194.7

9.62, d (7.6)

1'

120.1

2'

108.6

3'

149.1

147.5

4'

143.9

141.5

5'

149.1

147.5

6'

108.6

7.61, s

107.0

7.14, s

1''

105.1

5.75, d (7.2)

102.7

5.04, d (7.6)

2''

78.6

4.37, m

74.2

3.56, m

3''

72.2

4.22, m

76.6

3.49, t (8.8)

4''

76.2

4.22, m

71.0

3.43, t (9.0)

5''

76.2

4.37, m

74.4

3.56, m

6''

65.4

5.22, d (11.2);
4.97, dd (11.2, 6.0)

63.5

4.53, dd (11.6, 7.6);
4.45, dd (11.6, 2.4)

7''

167.1

3, 5-OMe

57.0

3.77, s

55.4b

3.80 b, s

3′, 5′-OMe

56.6

3.74, s

55.6b

3.81 b, s

119.3
7.61, s

107.0

7.14, s

166.4

Signals partially overlapped
Assignments may be interchanged

HRESIMS analysis of diplostephiosides B (2) identified a protonated ion at m/z 551.1745
[M + H]+, which in conjunction with the

13

C NMR data led to its molecular formula being

established as C26H30O13.71 The 1D NMR data (Table 7) for 2 were similar to those of 1 except
for the NMR resonances at δH 9.62 (H-9) and δC 194.7 (C-9), diagnostic for the presence of a
formyl functional group.71 These distinctive NMR resonances along with the difference in two
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mass unit in 2 implied that the C-9 hydroxymethylene group of diplostephioside A (1) was replaced
by a formyl group in 2. The HMBC correlations from the olefinic proton resonances at δH 7.42 (H7) and 6.65 (H-8) to the C-9 formyl resonance at δC 194.7 and the C-1 aromatic resonance at δC
130.5, as well as from the formyl proton resonances at δH 9.62 to an olefinic carbon resonances at
δC 127.6 (C-8) further supported the presence of a sinapyl aldehyde moiety (Figure 31).71 The βD-glucopyranosyl moiety of 2 was established on the basis of the coupling constant (J = 7.6 Hz)

of the anomeric proton and acid hydrolysis followed by GC analysis of the trimethylsilylated
derivative. The HMBC correlation of the anomeric proton resonance at δH 5.04 (H-1′′) and
aromatic carbon resonance at δC 136.8 (C-4) revealed the connectivity between C-1′′ of glucose
and C-4 of the sinapyl aldehyde moiety.71 The HMBC correlations of the deshielded 6′′-methylene
proton resonances at δH 4.53 and 4.45 and the ester carbonyl carbon resonance at δC 166.4 (C-7′′)
indicated the linkage between C-6′′ of the glucopyranosyl residue and the ester carbonyl of the
syringoyl moiety (Figure 31B).71 Consequently, the structure of compound 2, diplostephioside B,
was

defined

as

4-[6-O-(4-hydroxy-3,5-dimethoxy-benzoyl)-β-D-glucopyranosyloxy]-3,5-

dimethoxyphenylprop-7E-en-9-al, the name being generated by appropriate application of
phenylpropanoid numbering and nomenclature.
Compounds 3 and 4 were identified as (+)-lyoniresinol 3α-O-β-D-glucopyranoside and
sinapyl aldehyde, respectively, based on comparison of experimental and reported spectroscopic
and physico-chemical data.110,111
According to a previous study,71 compounds 1 and 2 impeded PTP1B activity with half
maximal inhibitory concentration (IC50) values of 81.0 and 25.9 M, respectively. These antiPTP1B metabolites were investigated for their detailed molecular interactions with PTP1B using
molecular docking studies, which suggested they bind to the allosteric site of the target
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Figure 32.71 Predicted binding poses of compounds 1 (left) and 2 (right) with key amino acid
residues shown. Dotted lines indicate hydrogen bonds.
phosphatase (Figure 32).71 To enhance this preliminary docking study, the conformational changes
of the WPD loop were investigated utilizing MD trajectory analysis monitoring the distance
between Trp179 and Arg221 upon the binding of 1 and 2, and the Wiesmann’s allosteric inhibitor
as a control ligand (Figure 33).101,104 The hydrogen bonding interaction between the
aforementioned residues played an indispensable role in the activation of the WPD loop for the
dephosphorylation catalytic reaction of PTP1B.104 Thus, the distance between the carbonyl
oxygen of Trp179 and the nitrogen of the guanidinium moiety of Arg221 (Figure 33A, see yellowdotted lines) was examined using 1200 ps MD simulation (Figure 33B) upon binding of
compounds 1 and 2, and the Wiesmann’s allosteric inhibitor to the allosteric site of PTP1B. The
MD trajectory analysis displayed that the distances between the aforementioned residues was
3.67–6.45, 3.50–6.15, and 3.95–6.53 Å upon simulation of the allosteric inhibition by the
Wiesmann’s inhibitor and compounds 1 and 2, respectively. The simulated distances of the two
atoms generated upon allosteric docking of compounds 1 and 2 were similar with that of the
Wiesmann’s allosteric inhibitor, implying the binding of compounds 1 and 2 to the allosteric site
stabilized and retained the inactivated (open) conformational state of the WPD loop. This
observation indicated that their allosteric inhibition precluded the closure of the WPD loop for
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formation of a tight binding pocket to implement the catalytic reaction of PTP1B for
dephosphorylation. The MD trajectory analysis was also in accord with previous studies101,104,105
demonstrating the distances of the aforementioned residues to be 4.15–5.22 Å for the open
(inactivated) conformation of the WPD loop, and 2.35–3.19 Å for the closed conformation,
validating our in silico investigation
on the WPD loop flexibility.
Figure 33. (B) MD trajectory analysis
of distance between the carbonyl
oxygen of Trp179 and the nitrogen of
the guanidinium moiety of Arg221.
The measured distance is indicated as
yellow-dotted lines in (A). The MD
software Desmond (Schrödinger,
LLC) was employed with reference to
previous studies.101,104,105 The crystal
structure was imported from the PDB
data bank (PDB ID: 1T48), optimized,
and minimized employing Protein
Preparation Wizard and redrawn using
Pymol
(Schrödinger
LLC.).
Wiesmann’s inhibitor indicates the
allosteric inhibitor co-crystallized
with 1T48101,103

CONCLUSIONS
This chapter elaborated details on the isolation and structure elucidation of
diplostephiosides A and B (1 and 2) from a rare South American plant species, D.
rhododendroides. Furthermore, MD analysis of 1 and 2 based on their docking simulation
validated that a glucosyl moiety flanked by two aromatic groups may be a suitable template that
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could be developed into selective PTP1B allosteric antagonists. Collectively, utilization of the
metabolites obtained from endangered and rare plant species may warrant a strong and sustained
emphasis on their conservation.

EXPERIMENTAL SECTION
General Experimental Procedures
See General Experiments sections in the previous chapters for routine experiment protocols.
The GC-MS data was recorded on a Hewlett Packard GC 6890 with an HP-5 column (cross-linked
5% phenyl methyl siloxane, 30.0 m  250 m  0.25 m) employing helium as carrier gas.
Plant Material
A Diplostephium rhododendroides Hieron. (Asteraceae) voucher sample was deposited in the
National Herbarium at the Smithsonian Institution (code 0CJS1259) and the EtOH extract of the
stems was obtained from Dr. D. Newman, Natural Products Repository, National Cancer Institute
(NCI).
Extraction and Isolation
The EtOH extract (15 g) was subjected to Si gel VLC (1500 g, 40-75 µm) and eluted with a
stepwise gradient of n-hexane/EtOAc [100:0, 75:25, 50:50, 25:75, 0:100 v/v (each 3 L)],
EtOAc/MeOH [75:25, 50:50, 25:75, 100:0 v/v (each 3 L)], and MeOH/H2O [75:25, 50:50, 100:0
v/v (each 3 L)] to give 12 fractions (Fr. 1 − 12). Fr. 6 (2.0 g) was further divided into 20 fractions
(Fr. 6-1 to 6-20) using a C18 HPLC column (21.2  250 mm, 5 m) with a gradient of MeOH/H2O
(35:65 → 60:40 v/v over 50 min, then 60:40 → 100:0 v/v for 5 min. Of these, Fr. 6-16 (99.0 mg)
was resolved on a C18 HPLC column (10.0  250 mm, 5 m) with a linear gradient of MeCN/H2O
(23:77 → 25:75 v/v for 60 min) to afford five sub fractions (Fr. 6-16-1 to 6-16-5). Fr. 6-16-3 was
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further purified employing C18 HPLC [10.0  250 mm, 5 m, MeCN/H2O (17:83 v/v)] to yield
compound 1 (tR 20 min, 8.3 mg). Purification of Fr. 6-16-5 using a C18 HPLC column (10.0  250
mm, 5 m) with a linear gradient of MeCN/H2O (23:77 → 25:75 v/v for 60 min) afforded
compound 2 (tR 20 min, 16.6 mg). Fr. 6-8 (15.6 mg) was chromatographed using a C18 HPLC
column [10.0  250 mm, 5 m, MeCN/H2O (17:83 v/v) for 30 min] to yield compound 3 (tR 25
min, 15.3 mg). Compound 4 (tR 38 min, 2.0 mg) was obtained from Fr. 6-18 (19.0 mg) employing
a C18 HPLC column [10.0  250 mm, 5 m, MeCN/H2O (23:77 v/v) for 60 min].
25

Diplostephioside A (1): white amorphous powder; [] D −15 (c 0.2, MeOH); UV (DAD) max
265.8 nm; 1H and

13

CNMR see Table 1; HRESIMS m/z: 575.1694; [M + Na]+ (Calcd. for

C26H32Na1O13: 575.1735)71
Diplostephioside B (2): white amorphous powder; []25
D −28 (c 0.2, MeOH); UV (DAD) max
292.4, 315.6 nm; 1H and 13C NMR see Table 1; HRESIMS m/z: 551.1745 [M + H]+ (Calcd. for
C26H31O13: 551.1765)71
Carbohydrate Analysis90
Compound 1 (1 mg) was dissolved in 0.5 mL of 1 N HCl, heated at 90 C for 2 h, and partitioned
with EtOAc and H2O (3  1 mL). The aqueous layer was neutralized with Ag2CO3 and centrifuged.
The dried supernatant was dissolved in anhydrous pyridine (1 mL) and 0.1 M L-cysteine methyl
ester hydrochloride in pyridine (2 mL) was added. The mixture was kept at 60 C for 1 hr. After
the reaction mixture was dried in vacuo, the residue was trimethylsilylated with 1trimethylsilylimidazole (0.5 mL) at 60 C for 5 min. The resulting mixture was partitioned between
n-hexane and H2O (3  1 mL) and the n-hexane fraction was analyzed utilizing a GC column (HP5ms, 5% phenyl 95% methyl polysiloxane, 30.0 m  250 m  0.25 m). The injector temperature
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was set at 260 C and the GC oven temperature was kept at 100 C for 1 min and increased to 280
C at a rate of 20 C/min using helium as carrier gas. The retention times of the standard sugars
were as follows: D-glucose (tR 10.84 min) and L-glucose (tR 10.95 min). In the hydrolysates of 1,
only D-glucose (tR 10.83 – 10.85 min) was detected (Figure S14).
PTP1B Assay
PTP1B (human, recombinant) was purchased from BIOMOL International LP (Plymouth
Meeting, PA). The enzyme activity was evaluated utilizing pnitrophenyl phosphate (pNPP), as
described previously.112 To each of 96 wells in a microtiter plate (final volume: 100 L) was added
2 mM pNPP and PTP1B (0.05  0.1 g) in a buffer containing 50 mM citrate (pH 6.0), 0.1 M
NaCl, 1 mM EDTA, and 1 mM dithiothreitol with or without the test compounds. After incubation
at 37C for 30 min, the reaction was quenched with 10 M NaOH. The amount of pnitrophenol
was evaluated by measuring the absorbance at 405 nm. The non-enzymatic hydrolysis of 2 mM
pNPP was adjusted assessing the increase in absorbance at 405 nm obtained in the absence of
PTP1B enzyme.
Molecular Dynamics (MD) Simulation
All MD simulations were performed using Desmond ver. 3.0 (Schrödinger LLC.) based on
protocols of previous PTP1B MD studies.105,113 Compounds 1 and 2, and 1T48 employed for
previous docking studies71,103 were minimized and solvated under the OPLS2005 force field with
the explicit simple point charge (SPC) water model. The systems were neutralized by the addition
of six sodium ions to replace SPC water molecules. MD simulations (1.2 ns) were carried out
under 300 K and 1.0 atm. The coordinates were saved with every 1.2 ps of energy and 4.8 of
trajectory.
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Figure 34. 1H (top) and 13C (bottom) NMR spectra (pyridine-d5) of diplostephiosides A (1)
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Figure 35. DQF-COSY and heteronuclear multiple-quantum correlation spectroscopy (HMQC)
spectra (pyridine-d5) of diplostephiosides A (1)
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Figure 36. HMBC and HRESIMS spectra of diplostephiosides A (1)
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Figure 37. Overlaid GC spectra of trimethylsilylated glucosyl moiety of 1 and chiral glucose
standards
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Figure 38. 1H (top) and 13C (bottom) NMR spectra (methanol-d4) of diplostephiosides B (2)
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Figure 39. COSY (top) and HMQC (bottom) spectra of diplostephiosides B (2)
77

Figure 40. HMBC and HRESIMS spectra of diplostephiosides B (2)
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INTRODUCTION
Pancreatic cancer has been recognized as a major cause of death in the West along with
breast cancer that will be addressed in Chapter 6. In 2015, an estimated 48,960 people in the US
will be diagnosed with pancreatic cancer and about 20,710 will die from the serious disease.114
These statistics render the malignancy to be the 4th leading cause of death from cancer in the
US,115 despite significant reductions in deaths and diagnoses of many other cancers.
Marine organisms harvested from global bodies of water have been validated as enriched
resources for providing diverse and potent anticancer drug leads.116 This is evidenced by the first
anticancer drug to reach the market ecteinascidin-743 (ET-743/trabectedin) from the Caribbean
tunicate Ecteinascidia turbinate,117 a cytotoxic cyclic depsipeptide, didemnin B from the tropical
Trididemnum solidum118 and kahalalide F from the herbivorous Hawaiian opisthobranch Elysia
rufescens and its prey Bryopsis spp.,119 halichondrin B from the Japanese sponge Halichondria
okadai120 which was modified into the recently FDA-approved anticancer drug, eribulin
mesylate,121 and pyrroloiminoquinones such as the discorhabdins and makaluvamines, from
diverse sponge sources worldwide, showing broad-spectrum antiproliferative effects and capable
of inhibiting topoisomerase II, respectively.122 Despite the extensive global investigations of
marine resources during the last few decades,116 the Aleutian Islands and invertebrate communities
have been underutilized in investigation of antineoplastic leads presumably because of limited
access. Consequentially, some marine environments in the Aleutian Islands remain unexplored,
which may hold a promise for providing novel and prospective prototypes for anticancer
chemotherapy. During our research group’s sponge collection conducted in deep waters off the
Aleutian Islands, more than 150 marine invertebrates were harvested and subjected to various
bioassay screenings to search for antiproliferative pharmacophores.123 Among the collected
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diverse sponge materials, Latrunculia spp. produced discorhabdin X (unpublished) possessing
intriguing ring systems based on a pyrroloiminoquinone architecture122 and exhibiting selective
cytotoxic activities in breast, brain, and pancreatic cancer cell lines (Table 8).
Table 8. Discorhabdin X and zones of inhibition (mm) against a wide range of cancer cell types.
DMSO and ecdysone are employed as negative controls and discorhabdin A and karlotoxin 2 as
positive controls.
OVCAR-5
(human ovarian cancer)

U251N
(human brain tumor)

MDA-MB-231
(human breast cancer)

PANC-1
(pancreatic cancer)

0
0
>1000
950
600
250
200
>1000
900
500

0
0

0
0

0
0

0
0

0
0

0
0

0
0

>1000
900
400
100

>1000
>1000
600
200

1000
500
400

900
700
350
200

>1000
850
700
150

>1000
800
500
200

>1000
650
200

900
750
350
100

950
750
400

800
600
350

500
250

700
500
200

300
300
200

1000
500
300

450
150
100

450
100
50

CCRF-CEM
(human leukemia)

LNCaP
(human prostate cancer)

>1000
300

MCF-7
(human breast cancer)

>1000
>1000
750

H-125
(human lung cancer)

Discorhabdin A

0
0
>1000
>1000
900
450
200
750
800
700

H-116
(human colon cancer)

Karlotoxin 2

0
0
950
700
500
250
150
1000
300
250

CFU-GM
(human hematopoietic
progenitor cell)

Discorhabdin X

2
2
1/4
1/16
1/64
2
2
1/4
1/16
1/64

Colon 38
(murine colon cancer)

DMSO
Ecdysone

Conc.
(mg/mL)

L1210
(murine leukemia)

Compound

The difficulty of developing prodrugs from marine invertebrates is evident because those materials
are generally unculturable, which implies that the marine-derived secondary metabolites should
be extracted and purified from specimens harvested by costly endeavors.116 This poses a serious
challenge to an adequate supply of marine natural products, which is a prerequisite for determining
their clinical potential in vivo. Even though synthetic approaches have played a role in resolving
the supply strain, large-scale synthesis demands a significant amount of time and resources, and
often fail in generating an appropriate amount of target compounds. Thus, it is of great importance
to fashion a viable synthetic route where each step comprising the synthetic strategy is wellestablished, and cost-effective starting materials and reagents are utilized.
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Among

the

pharmacophores

numerous
identified

marine

from

communities,

pyrroloiminoquinone-based alkaloids
such

as

discorhabdins

and

makaluvamines, briefly mentioned in
the
Scheme 1. The versatile intermediate I (N-demethylated
makaluvamine
A)
for
the
synthesis
of
pyrroloiminoquinone-based cytotoxic alkaloids

Introduction,

recognized

as

have
a

been

prospective

antineoplastic scaffold due to the

highly fused planar core structure.122 There have been previous attempts to synthesize cytotoxic
pyrroloiminoquinone alkaloids (Scheme 2). The core tricyclic indole architectures were prepared
via condensation of tryptamines with the quinone residue,124-127 or cyclization of 4aminoindole,128-131 4-chlorotryptamine,132 or 3-(azidoethyl)indole functionalities.133,134 However,
some of those strategies were developed based on costly starting materials, more than 10 reaction
steps, and relatively small reaction scales (see Scheme 2 for details). This makes it impractical that
those approaches are applied for a large scale synthesis of a marine-derived prodrug to address the
supply strain. This chapter delineates the development of a practical and scalable synthetic
approach (Hamann’s group approach in Scheme 2) employing inexpensive starting materials with
a large scale (230 mmol), and relatively short and straightforward reaction steps (eight steps) with
stable intermediates aiming at the synthesis of a sufficient amount of the versatile intermediate I
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for discorhabdin X and the related pyrroloiminoquinone-based cytotoxic alkaloids (Scheme 1).
A) Indole Approach
NH2
MeO

COOH

White's group (11 steps, 29 mmol, 2.5%)148

N

MeO

OMe

N

OTs

O

N

MeO

OMe PG

PG

O

Kita's group (14 steps, 5.3 mmol, 3.8%)141,142
Cava's group (13 steps, 128 mmol, 8.9%)143
Heathcock's group (11 steps, 31 mmol, 11.8%)
expensive starting material144

N

NHR

X
MeO

N

MeO

MeO

NH2
NHPG

OMe

N
H

N

N

O

Iwao's group (13 steps, 51 mmol,11%)149
N

OMe

N
H

PG

O

PG

N

N

MeO

N

MeO

N3
MeO

PG

Lown's group (8 steps, NA, 3.4%)147
Yamamura's group (14 steps, 10 mmol, 8.8%)
expensive starting material145,146

N

HN

MeO

PG

N

MeO

OMe PG

NH2

MeO

N

HN

MeO

OMe PG
Cl

MeO

O

O
N

MeO

PG

O

O

NHR

N

MeO

PG

O

MeO

OMe PG

O

Kita's group (seven steps, 0.5 mmol, 29%)
expensive starting material150,151

N
H

B) Tryptamine Approach (discussed in this chapter)
NH2
N3
MeO

NH2
OMe

MeO
OMe

N
H

MeO

N
OMe PG

N

Hamann's group (eight steps, 230 mmol, 2%)
N

MeO
O

PG

Scheme 2. Previous protocols for the synthesis of pyrroloiminoquinones. Part of this scheme was
adopted with permission from Hu, J.-F.; Fan, H.; Xiong, J.; Wu, S.-B. Chem. Rev. 2011, 111, 54655491. Copyright 2011 American Chemical Society. Reaction steps, scales, and overall yields for
each synthetic approach are shown in parentheses; PG: Protecting Group; NA: Not Available

RESULTS AND DISCUSSION
Unlike the previous protocols for synthesis of pyrroloiminoquinones (Scheme 2), the current
strategy in this chapter employs a tryptamine framework in I as the key intermediate. In order to
cost-effectively synthesize it, a one-pot synthesis approach utilizing palladium-catalyzed
annulation of o-iodoaniline 2 and aldehyde 5 was employed.135 With reference to reported
procedures, commercially available aniline 1 was iodinated employing iodine monochloride in a
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I
ICl
MeO

NH2
OMe

ether/Na2CO3
70%

MeO

NH2
OMe

1

2
O
NH2 phthalic anhydride

HO

3

140 °C
quantitative

N

4

O

OH
DMP
DCM/0 °C to r.t.
60%

O

O

N

5

O

Scheme 3. Preparation of coupling partners for the generation of dimethoxytryptamine via pdcatalyzed annulation
biphasic solution to generate 6-iodo-2,3-dimethoxyaniline (2) (70%, 66 mmol-scale) (Scheme 3)
for the Pd-catalyzed coupling reaction.136 Using Dess–Martin periodinane (DMP) oxidation, the
other aldehyde (5) partner was prepared from 4-phtalimidobutanol 4 (60%, 36 mmol-scale)137,138
that was synthesized simply by heating a mixture of phthalic anhydride and 4-aminobutanol 3
(quantitative, 230mmol-scale) (Scheme 3).139

Scheme 4. Pd-catalyzed cyclization via intramolecular Heck reaction and its mechanism. Pd:
Pd(OAc)2, DABCO: 1,4-diazabicyclo[2.2.2]octane
The coupling reaction was implemented with 2 and 5 via the intramolecular Heck reaction
catalyzed by the relatively inexpensive palladium source Pd(OAc)2 (50%, 10.5 mmol-scale)
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(Scheme 4) to generate
N-protected

6,7-

dimethoxytryptamine
6.135,140

The

catalyzed

Pd-

reaction

should be performed
carefully in terms of
Scheme 5. Side reactions dropping the yield of the palladiumcatalyzed cyclization reaction

the

purity

coupling

of

the

partners,

reaction concentrations, and an accurate amount of the catalyst used since the reaction was
involved with an intermolecular reaction to produce enamine and an intramolecular reaction to
generate the pyrrole functionality (Schemes 4 and 5). Indeed, residual ICl used to generate 2
rapidly oxidized phthalamic aldehyde 5 into its corresponding carboxylic acid 5a (Scheme 5). This
unexpected oxidation was also effected by residual oxygen in dimethylformamide (DMF), which
stresses the necessity of the solvent being rigorously degassed for the annulation reaction.
Moreover, an excessive amount of Pd(OAc)2 led to the dehalogenation of 2 to form 2a and this
deiodinated product subsequently reacted with 5a, leading to a significant reduction in yield of the
Pd-catalyzed
(Scheme

reaction
5).

The

phthalimide-protected 6
was
Scheme 6. Deprotection of the phthalimide group and successive
formation of azide 8
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deprotected

utilizing 85% hydrazine
monohydrate to obtain

6,7-dimethoxytryptamine 7 (60%).140 Next, Cu2+-catalyzed azido group transfer using
trifluoromethanesulfonyl azide (TfN3) was implemented to convert amine 7 to azide 8 (50%)141
(Scheme 6) that would play a key role in constructing a pyrroloiminoquinone template in later
steps. This azido transferring strategy, which has been predominantly used in aminosugar
synthesis, was also applicable for generating a target azide from a terminal amino group
comprising a tryptamine moiety, which verifies the substrate tolerance of such a reaction
application.

Scheme 7. Activated PIFA-mediated formation of the indole-based tricyclic structure followed
by transamination for synthesis of the end product I. t-BuOK: potassium tert-butoxide
The indole alkaloid bearing an ethylazido side chain 8 was used to attempt cyclization into
pyrroloiminoquinone

9

utilizing

the

hypervalent

iodine

(III)

reagent

[bis(trifluoroacetoxy)iodo]benzene (PIFA) activated by trimethylsilyl trifluoromethanesulfonate
(TMSOTf) in a mixture of (CF3)2CHOH (1,1,1,3,3,3-hexafluoroisopropanol, HFIP) and H2O.133
The reaction resulted in complex mixtures presumably because of side reactions occurring with
the activated PIFA at the nucleophilic centers in 8, i.e., N-1, C-2, and C-3 as discussed in previous
studies.133,142 Alternatively, the N-1 position of indoles was protected with electron-withdrawing
groups including an acetyl group (9, 75%) and treated with the activated PIFA in a mixture of
HFIP and H2O (50:1) to establish the formation of the corresponding pyrroloiminoquinone 10 as
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found in previous studies (50%) (Scheme 7).133,143 The transamination approach, which was
employed for such transformation from N-methylated 10 to makaluvamine A, was adopted to
convert 10 to I, the end product (60%) (Scheme 7).144
Even though some reaction steps in this chapter were validated to be scalable and versatile
with diverse substrates, those protocols were not successful in terms of the overall yield (2%) as
compared to a similar synthetic scheme developed by Kita’s group to generate the key intermediate
10 (Scheme 8, 29%).143 Thus, the Kita’s protocols are currently attempted to be reproduced and
optimized to synthesize 8. The commercially available starting material 11145 was treated with
oxalyl chloride in dry Et2O to synthesize 12 (85%), which was reduced into 13 using LiAlH4 in
dry THF (50%). The current yields are lower than the reported ones, which implies that
optimization of the currently performed reactions is necessary.

Scheme 8. Alternative synthetic route for the generation of 8; Yields in parentheses are the
reported ones.143
CONCLUSION AND FUTURE WORK
This chapter aimed to establish a scalable synthetic protocol comprised of well-established
synthesis protocols with low-priced starting materials to provide a sufficient amount of the
versatile intermediate I. A large amount of pyrroloiminoquinone I may resolve the supply strain
of pyrroloiminoquinone-based antineoplastic alkaloids such as discorhabdins, makaluvamines,
and discorhabdin X from deep waters off the Aleutian Islands to investigate their antineoplastic
potentials in vivo. Even though the current yields and scales of some steps need to be improved
for a large-scale synthesis of I, this chapter may serve as a stepping stone for the design of a costand time-effective synthetic strategy for the challenging synthesis of the indole-based tricyclic
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architectures and further examination of their therapeutic potentials for control of various cancer
types and related complications. Besides, further reproducing efforts and optimization of Kita’s
approach will be required.

EXPERIMENTAL SECTION
General Experiments
See General Experiments sections in the previous chapters for routine experiment protocols.
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO), Fischer Scientific (Pittsburgh,
PA), J & W PharmLab (Levittown, PA), Oakwood Chemical (West Columbia, SC), and
Waterstone Technology (Carmel, IN).
Synthesis Details
6-Iodo-2,3-dimethoxyphenylamine (2).136
A biphasic mixture composed of 440 mL of ether and 60 mL of saturated Na2CO3 was prepared
and 10.0 g (66 mmol) of 2,3-dimethoxyaniline was stirred in the dark. To this biphasic mixture
was added slowly 17 g (108 mmol) of iodine monochloride in 72 mL of ether. The reaction mixture
was stirred for 4 h and the layers were separated using a separation funnel. The ether layer was
washed five times with saturated Na2SO3 or Na2S2O3 to thoroughly remove residual iodine
monochloride and the combined ether layer was dried over anhydrous MgSO4 and concentrated.
The residue was purified using gravity silica gel chromatography to give 13 g (70%) of 1 as a
yellow solid; 1H NMR (400 MHz, CDCl3) δH 3.83 (s, 3H), 3.84 (s, 3H), 4.25 (brs, 2H), 6.19 (d,
1H, J = 9.0 Hz), 7.31 (d, 1H, J = 9.0 Hz); 13C NMR (100 MHz, CDCl3) δC 56.0, 60.1, 74.0,
104.4, 133.3, 135.4, 141.8, 153.2.
4-Phthalimidobutanol (4).139
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A mixture of phthalic anhydride (36 g, 240 mmol) and 4-aminobutanol (20 g, 240 mmol) was
heated to 145 °C. Nitrogen gas was streamed to remove water vapor. After cooling to r.t., the
reaction residue was dried and the product was obtained as a pale yellow oil (quantitative); 1H
NMR (400 MHz, CDCl3) δH 1.5 (p, 2H, J = 6.0 Hz), 1.6 (p, 2H, J = 7.6 Hz), 3.5 (t, 2H, J = 6.5
Hz), 3.7 (t, 2H, J = 7.2 Hz), 7.6 (m, 2H), 7.8 (m, 2H); 13C NMR (100 MHz, CDCl3) δC 24.9, 29.7,
37.6, 61.6, 123.0, 131.8, 133.8, 168.3.
4-Phthalimidobutanal (5).137,138
Compound 4 (5 g, 23 mmol) was dissolved in 50 mL of dichloromethane (DCM) in an ice bath
and Dess-Martin periodinane (15 g, 33 mmol) was added to the solution under argon. The reaction
mixture was stirred overnight, diluted with DCM, and added with saturated Na2S2O4 and NaHCO3.
The organic layer was dried over MgSO4 and concentrated. The residue was chromatographed
over gravity column chromatography to furnish 5 (60%) as a white power. 1H NMR (400 MHz,
CDCl3) δH 1.9 (p, 2H, J = 7.0 Hz), 2.5 (t, 2H, J = 6.9 Hz), 3.7 (t, 2H, J = 7.0 Hz), 7.6 (m, 2H), 7.8
(m, 2H), 9.7 (s);

13

C NMR (100 MHz, CDCl3) δC 21.0, 37.0, 40.9, 123.1, 131.8, 133.9, 168.2,

200.9.
3-(2-Phthalimidoethyl)-6,7-dimethoxyindole (6).140
A mixture of 2 (3 g, 11 mmol), 5 (2.3 g, 11 mmol), and DABCO (3.7 g, 33 mmol) in dry
dimethylformamide (DMF) (55 mL) was degassed using freeze-thaw-pump technique. Pd(OAc)2
(120 mg, 0.55 mmol) was added to the reaction mixture and it was heated at 85 ˚C for 12 – 24 h.
The reaction was monitored using TLC and additional palladium source was added to completely
consume 5. Upon the completion of the reaction, the mixture was cooled to room temperature and
diluted with water. The aqueous layer was extracted with EtOAc and the combined organic phases
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were washed with brine, dried using (MgSO4), and evaporated under reduced pressure. Purification
of crude product by gravity column chromatography provided the desired product (50%) and
starting material 2 (10%). 1H NMR (400 MHz, CDCl3) δH 3.1 (t, 2H, J = 7.8 Hz), 3.9 (s, 3H), 4.0
(s, 3H), 4.0 (t, 2H, J = 7.1 Hz), 6.86 (d, 1H, J = 7.0 Hz), 7.0 (s, 1H), 7.4 (d, 1H, J = 7.0 Hz), 7.7
(m, 2H), 7.8 (m, 2H); 13C NMR (100 MHz, CDCl3) δC 24.5, 38.4, 57.5, 60.8, 108.3, 112.7, 113.8,
121.7, 123.2, 124.2, 130.8, 132.2, 133.9, 134.5, 147.2, 168.3.
6,7-Dimethoxytryptamine (7).140
To a solution of 6 (900 mg, 0.4 mmol) in 90 mL of MeOH, 60% hydrazine monohydrate (9 mL,
180 mmol) was added and the mixture was proceeded for 2 h. After addition of saturated aqueous
NaHCO3 solution (100 mL), the solvent was evaporated and the aqueous phase was extracted
sufficiently with EtOAc (8 × 20 mL). The collected organic phase was dried over MgSO4 and
evaporated under reduced pressure, and the resultant residue was chromatographed on gravity
silica column chromatography using a mixture solvent (MeOH:CH2Cl2:NH4OH = 10:100:1) to
afford a light yellow oil 7 (28 mg) (60%). 1H NMR (400 MHz, CDCl3) 2.8 (t, 2H, J = 6.2 Hz), 3.0
(br t, 2H), 3.9 (s, 3H), 3.9 (s, 3H), 6.8 (d, 1H, J = 8.2 Hz), 6.9 (s, 1H), 7.2 (d, 1H, J = 8.4 Hz); 13C
NMR (100 MHz, CDCl3) 28.6, 41.6, 57.1, 107.5, 112.9, 113.4, 121.9, 124.2, 130.7, 134.2, 146.6.
3-(2-Azidoethyl)-6,7-dimethoxyindole (8).141
A triflyl azide solution was freshly prepared with reference to a previous study.141 Compound 7
(200 mg, 0.93 mmol) was dissolved in 3 mL of H2O and treated with potassium carbonate (192
mg, 1.39 mmol) and CuSO4 hydrate (1.4 mg., 8.8 mmol). To this solution was added MeOH (6
mL) and the triflyl azide solution. Additional MeOH was added for homogeneity of the reaction
mixture and the reaction mixture was stirred for 18 h. The mixture was filtered through cotton,
extracted with DCM three times and the organic layer was concentrated. The residue was applied
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to gravity silica column chromatography to obtain compound 8 (50%) as a pale yellow oil. 1H
NMR (400 MHz, CDCl3) 3.0 (t, 2H, J = 7.2 Hz), 3.6 (t, 2H), 3.9 (s, 3H), 4.0 (s, 3H), 6.9 (d, 1H, J
= 8.5 Hz), 7.0 (br s, 1H), 7.2 (d, 1H, J = 8.4 Hz); 13C NMR (100 MHz, CDCl3) 25.1, 51.6, 57.5,60.8,
108.3, 112.5, 113.5, 122.0, 124.0, 130.9, 134.6, 147.2.
1-Acetyl-3-(2-azidoethyl)-6,7-dimethoxyindole (9).143
A solution of 8 (0.50 mmol) in dry THF (5.0 mL) was added dropwise to a stirred suspension of
potassium t-butoxide (1.0 mmol) in dry THF (1.25 mL) under argon at an ice bath and stirred at 0
°C for 1 h. Acetyl chloride was added to the solution at 0 °C and the reaction mixture was stirred
for overnight at r.t. The mixture was quenched with H2O and extracted with CH2Cl2. The organic
layer was dried over MgSO4, evaporated, and subjected to gravity column chromatography to give
9 (75%). 1H NMR (400 MHz, CDCl3) 2.6 (s, 3H), 2.8 (t, 2H, J = 7.2 Hz), 3.5 (t, 2H), 3.9 (s, 3H),
3.9 (s, 3H), 6.9 (d, 1H, J = 8.5 Hz), 7.1 (d, 1H, J = 8.4 Hz), 7.3 (br s, 1H); 13C NMR (100 MHz,
CDCl3) 24.6, 25.2, 50.5, 56.9,60.7, 110.4, 113.7, 117.5, 124.6, 127.5, 128.9, 137.8, 151.3, 168.7.
7-Methoxy-3,4-dihydropyrrolo[4,3,2-de]quinolin-8(1H)-one (10).133,143
To a stirred solution of 9 (0.20 mmol) in HFIP/H2O (10 mL:0.20 mL), TMSOTf (0.500 mmol)
was added dropwise at 0 °C under argon and PIFA was added successively (0.24 mmol). After
stirring for 1.5 h at 0°C, the mixture was quenched with NaHCO3 and the solvent was evaporated.
The residue was extracted with CH2Cl2 and concentrated to be used for the next reaction without
purification due to its structural instability. 1H NMR (400 MHz, CDCl3) 2.8 (t, 2H, J = 8.3 Hz),
3.8 (s, 3H), 4.2 (t, 2H, J = 8.1 Hz), 6.1 (s, 1H), 6.9 (s, 1H)
7-Amino-3,4-dihydropyrrolo[4,3,2-de]quinolin-8(1H)-one (I).144
A mixture of 10 (113 mg, 0.5 mmol) and NH4Cl (270 mg) in MeOH (25 mL) was stirred r.t.
overnight. The mixture was concentrated and the resultant residue was purified utilizing gravity
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silica gel (CH2Cl2/MeOH/NH4OH = 80:20:1 → 70:30:1) to garner I (60%). The purified
compounds was treated with TFA in MeOH, resulting in the formation of its corresponding TFA
salt. 1H NMR (400 MHz, methanol-d4) 2.9 (t, 2H, J = 7.5 Hz), 3.8 (t, 2H, J = 7.7 Hz), 5.7 (s, 1H),
7.1 (s, 1H).
6, 7-Dimethoxy-3-(2-hydroxyethyl)indole (13)143
To a solution of 6,7-dimethoxyindole (11) (100 mg, 0.564 mmol) in dry Et2O (10 mL) a solution
of oxalyl chloride (0.064 mL, 0.734 mmol) in Et2O (8 mL) was added dropwise under argon at 0
°C and stirred for 2 h at 0 °C. EtOH (0.12 mL) was added to the reaction mixture at 0 °C and this
was stirred for 3 h r.t. NaHCO3 was added to quench the reaction and the mixture was extracted
with EtOAc. The organic layer was evaporated and proceeded to the next step without purification
to provide 12 (85%). 1H NMR (400 MHz, CDCl3) 1.3 (t, 3H, J = 7.2 Hz), 3.9 (s, 3H), 3.9 (s, 3H),
4.4 (q, 2H, J = 7.2 Hz), 7.0 (d, 1H, 8.9 Hz), 8.0 (d, 1H, 8.9 Hz), 8.4 (br d, 1H); 13C NMR (100
MHz, CDCl3) 14.0, 56.9, 61.1, 62.1, 111.0, 114.6, 117.4, 121.8, 130.8, 134.4, 137.2, 148.6, 162.8,
178.2. A solution of 12 (70 mg, 0.25 mmol) in THF (1 mL) was added dropwise to a suspension
of LiA1H4 (98 mg, 2.5 mmol) in THF (4 mL) under an argon atmosphere at 0 °C, and the mixture
was stirred in the ice bath for 20 mins. The mixture was carefully quenched with EtOAc, MeOH.
and brine. After filtration was performed through Celite, the filtrate was concentrated in vacuo.
The residue was dissolved with EtOAc and then evaporated to give pure 6 (1.13 g, quant) as a
colorless oil. 13C NMR (100 MHz, CDCl3) 28.7, 57.4, 60.8, 62.5, 108.1, 112.4, 113.7, 122.3, 124.1,
130.9, 134.4, 147.1.
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Figure 41. 1H and 13C NMR spectra of 2 (CDCl3)
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Figure 42. 1H and 13C NMR spectra of 4 (CDCl3)
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Figure 43. 1H and 13C NMR spectra of 5 (CDCl3)
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Figure 44. 1H and 13C NMR spectra of 6 (CDCl3)
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Figure 45. 1H and 13C NMR spectra of 7 (CDCl3)
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Figure 46. 1H and 13C NMR spectra of 8 (CDCl3)
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Figure 47. 1H and 13C NMR spectra of 9 (CDCl3)
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Figure 48. 1H spectra of 10 (CDCl3) and I (methanol-d4)
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Figure 49. 1H and 13C NMR spectra of 12 (CDCl3)
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Figure 50. 13C NMR spectra of 13 (CDCl3)
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CHAPTER 6: CHARACTERIZATION OF THE 3D STRUCTURE OF BRCA1-IRIS
INHIBITORY PEPTIDE EMPLOYING THE ENSEMBLE OF A HIGH-FIELD NMR
STUDY AND IN SILICO METHODS

INTRODUCTION
Breast cancer is the second most diagnosed cancer in women in the US146 and the estimated
new cases and deaths are 232,670 and 40,000, respectively, for 2014,147 imposing a serious burden
on health care communities and resources. The development of cytotoxic agents targeting breast
cancer is challenging because the malignant disease is diverse with various histological and
molecular subtypes carrying distinctive biological properties, resistance, and responses to
anticancer therapies.148 The most invasive breast cancer subtype is triple-negative breast cancer
(TNBC) characterized by a lack of estrogen and progesterone receptors, and human epidermal
growth factor receptor 2 amplification.149 These malignant features lead to conventional cytotoxic
agents, including tamoxifen and herceptin, being ineffective for cancer treatment.150 The TNBC
comprises ~15% of all the cases and shares many common oncogenic features with BRCA1associated tumors.149 Despite high susceptibility of TNBC to neo-adjuvant chemotherapy utilizing
paclitaxel, invasive breast cancer is prone to recurring upon visceral metastases.150 To date, there
is no comprehensive clinical strategy alleviating TNBC and its associated metastases, raising an
urgent need for the establishment of effective antiproliferative strategies for mitigation of this
aggressive breast cancer.
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BRCA1-IRIS (IRIS) is an oncogenic 1399 amino acid and expressed from the identical
locus as the tumor suppressor gene BRCA1.150-152 The up-regulated IRIS expression facilitates the
growth of breast tumors and circumvents apoptosis by curbing p53 activity and/or activating the
Akt pathway, and ultimately inducing survivin expression.153 This collectively results in the
resistance of the malignant cells to current chemotherapeutic strategies including etoposide,
ionizing or UV-radiation, and oxidative stress.153 The elevated expression of IRIS is typically
observed in TNBC cell lines and tumor cells particularly lacking the expression of the tumor
suppressor BRCA1.153 A recent study corroborates that IRIS employs its intron 11 peptide to
interact with other unknown proteins (X factors) in the oncogenic functions.154 Based on this study,
a mimetic IRIS-inhibitory peptide (IRIS-IP), composed of the oncogenic intron sequence attached
to a nuclear penetrating signal, was formulated to prevent the formation of tumorigenic complex
(Figure 51).154
RESULTS AND DISCUSSION

Figure 50. The schematic representation of the anti-oncogenic mechanism of IRIS inhibitory
peptide (A) and its sequence (B). X stands for X factors. The figure was obtained from Nature
Publishing Group with a permission via Rightslink® (License No. 3584830592805)
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The stereostructure of a cytotoxic molecule is crucial in fully examining the underlying
antineoplastic mechanism and formulating strategies to enhance the activity. To achieve this goal,
it is essential to acquire an NMR solution structure employing a wide array of NMR pulse
programs such as TOCSY,155 COSY,156 NOESY,157 1H-13C and 1H-15N HSQC,158 and recently
developed long range (LR)-HSQMBC.159 To complement biased and ambiguous structural
elucidation processes of macromolecules using NMR spectroscopy,160 homology modeling of
IRIS-IP with its sequence (Figure 51) was implemented with reflection of spatial and dihedral
information deduced from NMR data. Preliminary homology modeling was conducted using
Prime® (Schrodinger LLC.) and successfully built in chain A of rat metallophosphodiesterase
Mpped2a (PDB ID: 3RL3, resolution 1.42 Å) (Figure 52). The identity score between the two
protein structures calculated by the computational software was relatively low (28.1/100),
implying a unique folding pattern of IRIS-IP. Spatial distances, vitally important in elucidation of
3D structures of macromolecules, were acquired utilizing NOESY spectra recorded in DMSO-d6
with 5 or 10 % of trifluoroacetic acid (100
ms mixing time, 800 and 850 MHz
cryoprobe). The NMR solution structure
of IRIS-IP is being elucidated based on
the NOESY and TOCY data and the
current progress is shown in Figure 53.
Figure 51. A homology model of the
IRIS -IP on rat metallophosphodiesterase
(Prime and Pymol, Schrodinger LLC).
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These NOE data will be analyzed employing the SPARKY program161 and categorized into four
classes of distance based on signal intensities with reference to an internal standard: 2.5, 3.0, 4.0,
and 5.0 Å corresponding to strong, medium, weak, and very weak intensities, respectively.
This interproton distance information will be processed using CYANA 2.1 for an initial
solution structure calculation and the crude structure will be refined employing CNS 1.3 with a
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simulated annealing process.162,163 Among the calculated structures, 20 structures with lowest
energies without residual restraint violations will be chosen to represent the solution structure of
the IRIS-IP and their structure quality will be examined by protein structure validation software.164
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